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6ABSTRACT
ABSTRACT
Studies have shown that acute postoperative pain is still undertreated in many 
common surgical procedures such as tonsillectomy, as pain may go unnoticed in 
everyday practice. Recovery after tonsillectomy may be complicated also by post-
tonsillectomy hemorrhage (PTH), which can even be life threatening. The aim of this 
study was to investigate immediate complications after tonsillectomy particularly 
SDLQDQG37+DQGWRHYDOXDWHWKHHYLGHQFHUHJDUGLQJWKHDQDOJHVLFHɣHFWRIV\VWHPLF
analgesics and dexamethasone for post-tonsillectomy pain and whether topical 
URSLYDFDLQHLVHɣHFWLYHLQWKHSUHYHQWLRQRISDLQ6WXGLHV,DQG,,DUHUHWURVSHFWLYH
chart reviews including 1533 outpatients operated for tonsillectomy over one year 
in our institution, that analyzed the incidence of PTH in adult patients (Study I) 
and the incidence of all postoperative complications of pediatric patients (Study 
II), and their association with perioperatively administered medications. Study 
III is a systematic review and meta-analysis on analgesics and dexamethasone for 
the prevention or treatment of post-tonsillectomy pain in adults and adolescents 
LQFOXGLQJUDQGRPL]HGGRXEOHEOLQGSODFHERFRQWUROOHGVWXGLHV6WXG\,9LVD
prospective double-blind placebo-controlled study on topical ropivacaine applied 
to tonsillar beds after removal of tonsils for the prevention of post-tonsillectomy 
pain in 154 adult patients. 
In retrospective studies, PTH was the most common complication. Incidence 
of PTH in adults was 14.5%, and in pediatric patients 7.1%. In pediatric patients 
the overall incidence of unplanned postoperative contacts was 14%, (revisits 10%, 
UHDGPLVVLRQSDLQIHYHU32193DUDFHWDPROQRQVWHURLGDODQWL
LQÀDPPDWRU\DJHQWVGH[DPHWKDVRQHRUR[\FRGRQHZHUHQRWDVVRFLDWHGZLWKDQ
increased risk of postoperative complications in adult or in pediatric population. 
$PRQJSHGLDWULFSDWLHQWV WKHXVHRI ORFDOSHULWRQVLOODU LQ¿OWUDWLRQRI OLGRFDLQH
with epinephrine was associated with an increased risk of secondary PTH. In the 
V\VWHPDWLFUHYLHZWKHPDLQ¿QGLQJZDVWKHVFDUFLW\RIGDWDDQGVKRUWGXUDWLRQ
of follow-up in the included studies. Paracetamol, NSAIDs, dexamethasone, 
JDEDSHQWLQRLGVDQGGH[WURPHWKRUSKDQKDGZHDNWRPRGHUDWHDQDOJHVLFHɤFDF\RQ
the day of operation, dexamethasone in multiple doses beyond one day. The mean 
LQWHQVLW\RISDLQZDVPRGHUDWHWRVHYHUHIRUZHHNVGHVSLWHRIPHGLFDWLRQDPRQJ
adult patients in Studies III and IV. In prospective Study IV, topical ropivacaine 
IDLOHGWRUHGXFHSRVWWRQVLOOHFWRP\SDLQGXULQJWKH¿UVWSRVWRSHUDWLYHZHHNEXW
reduced the need for paracetamol-codeine during the second postoperative week 
(secondary outcome). 
7In conclusion, PTH is a common complication, especially in adults. The use of 
SHULWRQVLOODULQ¿OWUDWLRQRIOLGRFDLQHZLWKHSLQHSKULQHZDVDVVRFLDWHGZLWKLQFUHDVHG
risk of secondary PTH among pediatric patients. Systematic review reveled that the 
HYLGHQFHRQHɤFDF\RIDQDOJHVLFVIRUSRVWWRQVLOOHFWRP\SDLQLVVWLOOPLQLPDOGXH
to lack of good quality studies with long enough follow-up. Pain intensity is usually 
moderate to severe for more than one postoperative week. Single analgesics are not 
HɣHFWLYHHQRXJKWRSURYLGHFOLQLFDOO\PHDQLQJIXOUHGXFWLRQRISDLQLQWHQVLW\DQG
thus multimodal pain management is needed. Topical ropivacaine failed to reduce 
SRVWWRQVLOOHFWRP\SDLQGXULQJWKH¿UVWSRVWRSHUDWLYHZHHNEXWVHHPHGWRPRGLI\
pain during the second postoperative week.
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ABBREVIATIONS
$+, $SQHDK\SRSQHDLQGH[LVXVHGIRUFODVVL¿FDWLRQRIVHYHULW\RI
sleep apnea. It is represented by the number of apnea and 
hypopnea events per hour of sleep which must last for at least 10 
seconds and be associated with a decrease in blood oxygenation.
APS-OPC Acute Pain Service Outpatient Clinic
ASA American Society of Anesthesiologists
BPI Brief Pain Inventory
&, &RQ¿GHQFHLQWHUYDO
COX Cyclooxygenase (enzyme)
EMA European Medicines Agency
ESPA European Society for Paediatric Anaesthesiology
IQR interquartile range
i.v. Intravenous (route of administration)
Na+ Sodium
NMDA N-methyl-D-aspartate
NNT Number needed to treat
Nociceptor  Pain receptor, sensory neuron that responds to damaging 
or potentially damaging stimuli by sending “possible threat” 
signals to the spinal cord and the brain
NRS Numeric rating scale
NRSr Numeric rating scale at rest
NRSs Numeric rating scale on swallowing
16$,' 1RQVWHURLGDODQWLLQÀDPPDWRU\GUXJ
OIH Opioid-induced hyperalgesia
OR Odds ratio
OSA Obstructive sleep apnea
oSDB Obstructive sleep-disordered breathing
Outpatient surgery Surgery that does not require an overnight hospital stay; 
 same as day surgery
PACU Post-anesthesia care unit
p.o. Peroral (route of administration)
Pod Postoperative day
PONV  Postoperative nausea and vomiting
PTH  Post-tonsillectomy hemorrhage
37+SULPDU\ 3RVWWRQVLOOHFWRP\KHPRUUKDJHZLWKLQKRXUVRIRSHUDWLRQ
37+VHFRQGDU\ 3RVWWRQVLOOHFWRP\KHPRUUKDJHDIWHUKRXUVDIWHURSHUDWLRQ

Abbreviations
RCT  Randomized controlled trial
RR Risk ratio
SD  Standard deviation
VAS  Visual analog scale 
VRS Visual rating scale 
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1. INTRODUCTION
Tonsillectomy is the most common otolaryngological procedure globally and is 
usually performed as an outpatient surgery. In Finland, approximately 7900 
procedures, and in the United States more than 500 000 procedures, are performed 
annually.1-5 Recovery may be complicated by post-tonsillectomy hemorrhage (PTH), 
intense pain, postoperative nausea and vomiting (PONV), and dehydration.6-7 PTH 
can even be life threatening.
Although tonsillectomy is a common operation, consensus on optimal pain 
management strategy is still missing. NSAIDs and dexamethasone are used in 
the prevention and treatment of post-tonsillectomy pain and reduction of opioid 
requirements and PONV, however association with an increased risk of PTH has 
been suspected.8-18 In adults, the indication for tonsillectomy is most commonly 
recurrent or chronic tonsillitis, whereas in pediatric patients it is hypertrophy. 
Chronic tonsillitis requires more dissection and coagulation, which leads to more 
intense pain, and therefore weak opioids are usually needed. For pediatric patients, 
use of opioids has been recently restricted due to reports of serious respiratory 
depression. Fortunately, tonsillotomy in which only part of tonsils are removed, 
has become more common technique and as it is less painful, opioids are not 
necessarily needed.4/RFDODQHVWKHWLFVDUHXVHGFRPPRQO\ LQGLɣHUHQW W\SHVRI
surgeries as part of multimodal analgesia. For post-tonsillectomy pain, modest 
HɤFDF\RIORFDODQHVWKHWLFVKDVEHHQIRXQGLQSHGLDWULFSRSXODWLRQVEXWLQDGXOWV
only small heterogeneous studies with less than optimal quality exist.
The incidence of unplanned postoperative contacts to hospital is often used as an 
estimate of quality of perioperative treatment. In our institution in a prospective 
VWXG\LQSHGLDWULFSDWLHQWVWKHLQFLGHQFHRIXQSODQQHGUHWXUQYLVLWVZDV
37+XQDEOHWRHDW
In the present thesis, the main purpose was to study how patients recover from 
tonsillectomy with emphasis on the most common postoperative complications—
PTH and pain. The incidence of complications in our institution (PTH in adults 
and all immediate complications in pediatric patients), and whether perioperative 
PHGLFDWLRQLQÀXHQFHVWKHPZDVLQYHVWLJDWHGLQD ODUJHUHWURVSHFWLYHVWXG\7KH
HɤFDF\RISHULRSHUDWLYHDQDOJHVLFVDQGGH[DPHWKDVRQHIRUSRVWWRQVLOOHFWRP\SDLQ
was studied in a systematic review and meta-analysis. Local anesthesia with topical 
ropivacaine for the prevention of post-tonsillectomy pain in adults was examined 
in a prospective study.  
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2. REVIEW OF LITERATURE
7RQVLOOHFWRP\ZDV¿UVWGHVFULEHGLQ:HVWHUQOLWHUDWXUHE\&HOVXVLQʃʆ and 
in Hindi medicine 3000 years ago, being probably one of the oldest surgical 
procedures.
The tonsils are lymphatic tissue and are part of the body’s immune system, the 
part in which immune responses against antigens entering the body through the 
mouth or nose are initiated. The greatest immunologic activity of the tonsils is found 
between the ages of 3 and 10 years. The epithelium of the tonsils is cryptic and 
contains a system of specialized channels lined by “M” cells, which take up antigens 
into vesicles and transport them to the lymphoid follicles, where dendritic cells and 
macrophages process the antigens and present them to helper T lymphocytes which 
then stimulate proliferation of follicular B lymphocytes and their development into 
either antibody-expressing B memory cells or plasma cells that produce antibodies.30 
In chronic tonsillitis, the controlled process of antigen transport and presentation 
is altered due to shedding of the M cells from the tonsil epithelium.30 The tonsillar 
lymphocytes can become so overwhelmed with antigenic stimulation that they 
may be unable to respond to other antigens. Once this immunologic impairment 
occurs, the tonsil is no longer able to function adequately in local protection or 
to reinforce the secretory immune system of the upper respiratory tract.30 The 
therapeutic advantage of removing recurrently or chronically infected tonsils causing 
symptoms such as pain in throat and fever, is based on this pathology.
The main indications for tonsillectomy are as mentioned chronic tonsillitis, 
recurrent peritonsillar abscess, and tonsillar hypertrophy causing obstructive sleep-
disordered breathing (oSDB) or sleep apnea, periodic fever (pediatric patients), and 
suspicion or treatment of malignancy.31 oSDB is a clinical diagnosis “characterized by 
obstructive abnormalities of the respiratory pattern or the adequacy of oxygenation 
or ventilation during sleep (snoring, mouth breathing, and pauses in breathing).” 
oSDB includes a spectrum of obstructive disorders that increase in severity from 
primary snoring to obstructive sleep apnea (OSA). Studies have shown that disease-
VSHFL¿FDQGJOREDOTXDOLW\RIOLIHLPSURYHDIWHUWRQVLOOHFWRP\KDVEHHQSHUIRUPHG
for recurrent or chronic sore throat, or oSDB.
7RQVLOOHFWRP\LVGH¿QHGDVDVXUJLFDOSURFHGXUHSHUIRUPHGZLWKRUZLWKRXW
adenoidectomy that completely removes the tonsil, including its capsule, by 
dissecting the peritonsillar space between the tonsil capsule and the muscular 
wall (Figure 1). In our institution (Helsinki University Hospital, Department 
of Otorhinolaryngology—Head and Neck Surgery), the main technique is cold 
dissection in which tonsils are removed with cold steel instruments and hemostasis 
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is achieved by coagulating bleeding vessels with bipolar forceps as necessary. The 
area is left open to heal, and sutures are not needed. Other techniques include 
hot techniques (bipolar diathermy scissors, ultrasound scissors, coblation) and 
variations of these. Tonsillectomy is usually performed under general anesthesia 
with endotracheal intubation. For pediatric patients a (reinforced) laryngeal 
mask instead of endotracheal tube is also being used.33 In tonsillotomy, tonsillar 
tissue causing obstructive symptoms is removed partially without touching the 
surrounding tissue (performed mainly for pediatric patients).
Tonsillectomy is usually performed as outpatient surgery, and patients are 
discharged on the day of operation, a practice that has proven to be safe with 
appropriate patient selection.34 In many institutions, including ours, patients are 
discharged 6 hours after surgery. Most of primary PTHs occur within 6 hours after 
VXUJHU\DQG37+EHWZHHQ±KRXUVLVH[WUHPHO\XQOLNHO\35 Therefore, monitoring 
for primary hemorrhage using overnight admission is not useful. Patients prefer 
recovering at home, and in addition risk of infections and costs are reduced.   
A. B. C. D.
Figure 1. Tonsillectomy. A. On the day of operation. B. Sixth postoperative day; ﬁbrin clot starts to detach, 
and the risk of post-tonsillectomy hemorrhage is at its highest. C. Two weeks after tonsillectomy healing is 
not yet complete. D. Four months after surgery the mucosa of the tonsillar beds has healed. Reproduced 
with permission from Mäkinen LK, Nokso-Koivisto J. Tonsillectomy. Duodecim 2019;135:69-75. 
2.1. COMPLICATIONS AFTER TONSILLECTOMY
2.1.1. INCIDENCE OF COMPLICATIONS
In large register studies, the incidence of unplanned postoperative return visits is 
DURXQG±DPRQJSHGLDWULFSDWLHQWV37+±GHK\GUDWLRQ±SDLQ±
readmissions 0.5–1%); in adult patients two times higher (except for dehydration, 
which is more common among pediatric patients).36,37 In prospective studies the 
incidence of complications seems to be even higher, most probably due to more 
accurate data gathering.7 ,QDSURVSHFWLYHVWXG\ LQ'HQPDUN LQ LQFOXGLQJ
614 tonsillectomy outpatients, the incidence of unplanned postoperative contact 
ZDVSDLQ37+3219UHDGPLVVLRQVDQGWKH LQGLFDWLRQ
of chronic tonsillitis and higher age increased the risk of unplanned contact (31% 
16
 5HYLHZRIOLWHUDWXUH
of adults vs. 18% of children).7 ,QRXU LQVWLWXWLRQLQDSURVSHFWLYHVWXG\
including 100 pediatric patients, the incidence of unplanned return visits was 13% 
37+XQDEOHWRHDW
Other complications include fever (usually 18–36 hours after surgery), respiratory 
problems (laryngospasm, obstructive symptoms, pulmonary edema as a result of 
sudden relief of the excess positive end-expiratory pressure after the tonsils are 
removed), operative trauma to the surrounding tissues, nerve lesions of the nervus 
lingualis (taste disorder, neuralgia) and glossopharyngeal nerve (velopharyngeal 
LQVXɤFLHQF\ZLWKQDVDOUHJXUJLWDWLRQVHFRQGDU\QHXUDOJLDRWDOJLDDQGGLVORFDWLRQ
of cervical vertebra (patients with Down syndrome have atlantoaxial joint laxity 
and are at risk of subluxation during manipulation of the neck and suspension 
with a mouth gag).38 Although tonsils are lymphatic tissue and part of the body’s 
immune system, and minor alterations in immunoglobulin concentrations in serum 
have been demonstrated in some studies, their removal has not been associated 
with increased incidence of upper respiratory tract infections.30,40 However, an 
increased risk of rare deep neck infections has been reported (1.7 times greater in 
tonsillectomized patients).41
Reported rates of outpatient tonsillectomy mortality varies between 1 in 
18 000 to 1 in 56 000 internationally.31 About one-third are related to PTH, the 
rest to aspiration, cardiopulmonary failure, electrolyte imbalance, or anesthetic 
complications.31 Airway compromise is the major cause of injury and death in 
malpractice claims.37 In Finland, 4 patients (age 15–34 years) have died between 
±GXHWRVHFRQGDU\37+ LQWZRFDVHVGD\VSRVWRSHUDWLYHO\ LQWZR
FDVHV±GD\VSRVWRSHUDWLYHO\XQSXEOLVKHGGDWD$UFKLYHRIGHDWKFHUWL¿FDWHV
Statistics Finland).
2.1.2. POST-TONSILLECTOMY HEMORRHAGE
37+RFFXUVLQDWZRSHDNPRGHSULPDU\37+ZLWKLQKRXUVRIRSHUDWLRQDQG
VHFRQGDU\37+KRXUVDIWHURSHUDWLRQXVXDOO\DWDURXQGSRVWRSHUDWLYHGD\V
to 7, secondary PTH being more common.The pattern of PTH and pain can be 
understood by pathology of tonsillectomy and by the physiological healing process. 
Surgical and thermal damage to the mucosa, muscles, and nerve endings  cause 
LQÀDPPDWLRQVZHOOLQJDQGSDLQDVSKDU\QJHDOQRFLFHSWRUVDUHVWLPXODWHG Pain 
usually reaches its maximum at postoperative days 3–7 (depending on the extent 
RIVXUJHU\ZKLFKFRUUHVSRQGVWRWKHPD[LPDOZRXQGLQÀDPPDWLRQGRFXPHQWHG
LQH[SHULPHQWDOPRGHOV$VWKHFRDJXODWLRQFDVFDGHDFWLYDWHVD¿EULQFORWLVIRUPHG
RQWRSRI WKHVFDUXQGHUZKLFKUHQHZLQJHSLWKHOLXPVWDUWV WRJURZ7KH¿EULQ
clot detaches on around the seventh postoperative day, leaving the regenerative 
capillaries open to irritation, and during this time secondary PTH is most common. 
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When epithelialization is completed at the end of the second postoperative week, 
37+UDUHO\RFFXUVDQGSDLQGLPLQLVKHVVLJQL¿FDQWO\
The incidence of PTH in the literature varies from 0 to 40% due to the inconsistent 
criteria of bleeding  and type of data gathering. If data are analyzed more systemically, 
the range narrows down.43 Results depend on whether data collected are from patient 
questionnaires including all minor bleeding episodes that stop spontaneously (in 
prospective studies), patient charts including all contact with the hospital due to 
bleeding (in retrospective studies), or register studies including only revisits and 
UHRSHUDWLRQVPDNLQJLWGLɤFXOWWRFRPSDUHUHVXOWV
For systematic improvement of care and benchmarking, national quality registers 
are nevertheless essential. National quality registers are the most developed in 
Sweden, including over 100 medical quality registers, of which nine focus on ear, 
nose, and throat diseases.44 At the moment, an international tonsil surgery quality 
register is being established for Denmark, Finland, Norway, and Sweden by the 
Nordic Tonsil Surgery Register Collaboration.45
A higher risk of PTH is associated with indication for surgery (secondary 
hemorrhage more common with chronic tonsillitis and previous peritonsillar 
abscess than with tonsillar hypertrophy), male gender, and older age.46,47 In adults, 
indication is mainly recurrent infection requiring more dissection, and therefore 
risk of PTH and pain intensity may increase, compared with pediatric patients 
operated mainly for tonsillar hypertrophy. Hot techniques (bipolar diathermy 
VFLVVRUVXOWUDVRXQGVFLVVRUVFREODWLRQZKLFKDɣHFWDGHHSHUDQGODUJHUDUHDDURXQG
the tonsils, are associated with a higher risk of secondary PTH and an increased 
pain intensity compared with cold steel dissection.48 Tonsillotomy has lower risk of 
PTH than tonsillectomy, and therefore tonsillotomy has become the preferred type 
of tonsil surgery for pediatric patients in recent years.36 In tonsillotomy, tonsillar 
tissue causing obstructive symptoms is removed partially without touching the 
surrounding tissue, resulting in less pain, a reduced number of days of analgesic 
use, fewer days to return to a normal diet, less dehydration, and a lower rate of 
PTH and readmissions.49-50 
2.1.3. POST-TONSILLECTOMY PAIN
Studies have shown that managing postoperative pain is still a challenge, and in 
some operations that have high pain intensities patients do not receive enough 
analgesia. Although good analgesic techniques exist, they are not used, possibly 
because pain goes underestimated in everyday practice. A prospective cohort study 
RISDWLHQWVFROOHFWHGGDWDRQSDLQLQWHQVLW\RQWKH¿UVWGD\DIWHUVXUJLFDO
SURFHGXUHVLQ*HUPDQ\LQ It found that patients reported high pain scores 
after many “minor” surgical procedures, including tonsillectomy, appendectomy, 
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cholecystectomy, and hemorrhoidectomy, which ranked among the 25 procedures 
with highest pain intensities. These patients typically received no or low doses of 
opioids which, according to the authors, indicated that high pain intensities were 
often ignored or not taken seriously, so that analgesic administration was delayed 
DQGRULQVXɤFLHQW
Post-tonsillectomy pain has been known to be intense, lasting for several days; 
however, in most studies follow-up periods cover only the early postoperative days.53 
Postoperative pain types were analyzed in a questionnaire-based study on 335 
patients in 2012 in Austria.54)LYHSDLQW\SHVZHUHLGHQWL¿HG)LJXUH3DLQW\SH
,FKDUDFWHUL]HGE\DFRQVWDQWORZOHYHORISDLQZDVPRUHFRPPRQLQSHGLDWULF
SDWLHQWV\HDUVFRPSDUHGZLWKDGXOWVS6HYHUHDQGRULQFUHDVLQJ
SDLQW\SHV,,,,9DQG9ZHUHPRUHFRPPRQLQDGXOWVS,QSDLQW\SHV
,9DQG9SDLQLVVHYHUHIRUZHHNV7KHPRVWIUHTXHQWSDLQW\SHW\SH,,
with severe pain until the sixth to seventh postoperative day, then declining, was 
VLPLODUO\GLVWULEXWHGEHWZHHQERWKDJHJURXSVS 3DWLHQWVZLWKLQFUHDVLQJ
SDLQW\SHV,,,DQG,9DQGSDLQW\SH9VKRZHGVLJQL¿FDQWO\KLJKHUULVNIRU37+
Figure 2. Incidence of pain types (percentage; %). Pain intensity reported as mean value during each 
period. Reproduced with permission from Sarny S, Habermann W, Ossimitz G, Stammberger H. Signiﬁcant 
post-tonsillectomy pain is associated with increased risk of hemorrhage. Ann Otol Rhinol Laryngol. 
2012;121:776-81.54 
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2.2. PAIN PATHWAYS AND PROCESSING
The pain stimulus caused by tissue damage leads to a series of electrical and chemical 
events that ultimately result in sensing and experiencing pain. Physiological events 
that lead to pain sensation in the nervous system can be divided into four stages 
(Figure 3). Initially, a pain stimulus is produced in the tissue when the nociceptors 
QHUYHHQGLQJVLQWKHSULPDU\DɣHUHQWQHXURQVRUDVUHFHQWO\GLVFRYHUHGSDLQ
UHFHSWLYH6FKZDQQFHOOVDUHDFWLYDWHGWKURXJKPHFKDQLFDOFKHPLFDOLQÀDPPDWRU\
mediators), or thermal stimulation of the tissue that causes electrochemical 
activation of nerve endings, leading to the generation of action potentials in the 
nerve cell (transduction). The pain signal is then transmitted through the nerve 
cells to the parts of the central nervous system (transmission) where the pain is 
sensed (perception). Pain is altered in the nervous system by inhibitory descending 
pathways (modulation).55
$IWHULQMXU\FRQWLQXRXVUHOHDVHRILQÀDPPDWRU\PHGLDWRUVVHQVLWL]HVQRFLFHSWRUV
marked by a decreased threshold for activation (peripheral sensitization), clinically 
observed in the tissue injury area as primary hyperalgesia (pain is perceived as more 
painful than it would otherwise have been) and pain response from stimuli which 
do not normally provoke pain (allodynia), which are normal protective responses, 
that subside as tissue is healed. Strong and long-lasting noxious input from the 
periphery may result in central sensitization (persistent postinjury changes in the 
central nervous system that result in pain hypersensitivity) and hyperexcitability 
H[DJJHUDWHGDQGSURORQJHGUHVSRQVLYHQHVVRIQHXURQVWRQRUPDODɣHUHQW LQSXW
after tissue damage).56&OLQLFDOO\WKHXQDɣHFWHGQRUPDODUHDDURXQGWKHWLVVXHLQMXU\
becomes sensitized to pain (secondary hyperalgesia), its extent correlating with 
the risk of chronic postsurgical pain / persistent postoperative pain. The subacute 
phase (4–6 weeks postoperatively) seems to be critical in that if pain continues, or 
gets worse, the underlying central sensitization process is maintained, and long-
lasting neuroplastic changes in the dorsal horn of the spinal cord may occur (“pain 
memory”), which may cause acute pain to become chronic.57,58 
The neural circuits in the dorsal horn are complex, and various neurotransmitters, 
second messengers (e.g., substance P, protein kinase C), and receptors (e.g., 
N-methyl-D-aspartate [NMDA]) are involved in the process of nociception and in 
acute and chronic pain.59

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Figure 3. The pain pathway in the central and peripheral nervous systems and the sites of action for each 
class of medication. COX-2, cyclooxygenase-2; NMDA, N-methyl D-aspartate; NSAIDs, nonsteroidal anti-
inﬂammatory drugs. Reproduced with permission from Kohring JM, and Orgain NG. “Multimodal Analgesia 
in Foot and Ankle Surgery.” The Orthopedic Clinics of North America 2017;4:495-505.

2.3. PAIN MEASUREMENT
Pain is a personal experience. The International Association for the Study of Pain 
,$63GH¿QHVSDLQDV³DQXQSOHDVDQWVHQVRU\DQGHPRWLRQDOH[SHULHQFHDVVRFLDWHG
with actual or potential tissue damage or described in terms of such damage”. 
Measuring pain and its changes are needed in evaluating treatment responses in 
clinic practice and in research. The Numerical Rating Scale (NRS), Visual Analogue 
Scale (VAS), Verbal Rating Scale (VRS), and Faces Pain Scale-Revised (FPS-R) are 
validated measures of pain intensity.60 The most commonly used is VAS (visual 
analogue scale), a continuous scale comprised of a horizontal line, usually 10 
centimeters (cm) in length. Patient marks a vertical line at the intersection, which 
KHVKHHVWLPDWHVWRUHÀHFWWKHLQWHQVLW\RISDLQ/HIWHQGRI9$6OLQHFRUUHVSRQGV
to a situation where the patient has no pain at all, while the right end corresponds 
to the worst possible pain. In NRS (numeric rating scale), numbers (usually from 
0-10) describe pain intensity in which 0 stands for no pain, 1 to 3 mild pain, 4 to 
6 moderate pain, and 7-10 severe/strong pain. In VRS (verbal rating scale) words 
describe intensity of pain (4 to 6 points) which can be converted to numbers. Children 
of 3-4 years of age can use simple verbal scales and graphical pain facial scales such 
DV)565RU:RQJ%DNHUIDFHVVFDOHDQGDWWKHDJHRI¿YHRUPRUH9$6DQGLWV
PRGL¿FDWLRQV,Q\RXQJDQGVHYHUHO\LOOFKLOGUHQSDLQDQGLWVFKDQJHVDUHDVVHVVHG
by observer (changes in behavior, posture, facial expressions, sound, skin color, 
heart rate, and response to treatment).  When measuring pain, both pain at rest and 
during movement (dynamic pain) should be assessed.61 Consumption of analgesics 
and need for rescue medication are also used as end-points/outcomes in research. 
Currently, more comprehensive patient reported outcomes (PROs) of the 
UHFRYHU\H[SHULHQFHSDLQVOHHSIXQFWLRQPRRGWKDWUHÀHFWWKHLPSDFWRIDGLVHDVH
condition to daily life, are recommended to be used. Brief pain inventory (BPI) is 
a validated tool that documents both the intensity of pain (sensory dimension) 
and interference of pain in the patient’s life (reactive dimension). It was originally 
developed by World Health Organization (WHO) for cancer patients and has been 
IRXQGUHOLDEOHDQGYDOLGLQGLɣHUHQWSDLQVWDWHVDFURVVFXOWXUHVDQGODQJXDJHV  
2.4. PAIN MANAGEMENT PRINCIPLES 
3DWLHQWFHQWHUHGFDUH LVD IRXQGDWLRQDQGVRXUFHRIHɣHFWLYHVDIHDQGYDOXDEOH
treatments. It is achieved by building a partnership between clinician and patient. 
Clinician shares information and discusses treatment options gathering information 
on patient’s own expectations and goals - open dialogue in which patient is involved 
in treatment considerations, called shared decision making.  

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For acute postoperative pain, multimodal (opioid-sparing) analgesia has 
become the standard of care. According to the International Association for the 
6WXG\RI3DLQ,$63LWLVGH¿QHGDV³WKHFRQFXUUHQWXVHRIVHSDUDWHWKHUDSHXWLF
LQWHUYHQWLRQVZLWKGLɣHUHQWPHFKDQLVPVRIDFWLRQZLWKLQRQHGLVFLSOLQHDLPHGDW
GLɣHUHQWSDLQPHFKDQLVPV´ZLWKWKHUDWLRQDOHWRWDUJHWVLPXOWDQHRXVO\PXOWLSOH
SODFHVLQWKHQRFLFHSWLYHV\VWHPDWVPDOOHUGRVHVWRPD[LPL]HWKHDQDOJHVLFHɣHFW
while minimizing adverse events. Multimodal analgesia is an integral part of 
enhanced recovery after surgery (ERAS) concept, which is a perioperative care 
pathway designed to achieve early recovery for patients undergoing major surgery 
(erassociety.org).   
Minimizing need for opioids is essential for optimizing recovery of patients after 
VXUJHU\$OWKRXJKRSLRLGVDUHWKHPRVWHɣHFWLYHDQDOJHVLFVWKH\KDYHPDQ\DGYHUVH
HɣHFWV+LJKGRVHVRILQWUDRSHUDWLYHRSLRLGVPD\SURGXFHFRXQWHUHɣHFWVEHFDXVH
of neuroadaptation; enhancement of existent pain and facilitation of chronic pain 
development.61 Opioid tolerance (pharmacological concept) and opioid-induced 
hyperalgesia (OIH, a clinical syndrome) develop, opioid requirements increase 
postoperatively, and recovery does not proceed optimally.  Opioid-sparing therapeutic 
interventions that are combined include regional anesthesia, non-opioid analgesics, 
DQGDGMXYDQWVWKDWRSWLPDOO\KDYHDGGLWLYHRUV\QHUJLVWLFHɣHFWVSURGXFLQJVXSHULRU
DQDOJHVLDZKLOH GHFUHDVLQJ RSLRLGUHODWHG VLGH HɣHFWV 6HYHUDO DGMXYDQW GUXJV
commonly used in perioperative anesthesia attenuate the development of OIH: 
ketamine, gabapentinoids, magnesium, dexmedetomidine, lidocaine, and nitrous 
oxide, also called “antihyperalgesic adjuvants.” 63 They are increasingly studied for 
WKHLUHɤFDF\WRSURYLGHRSLRLGOHVVDQGRSLRLGIUHHDQHVWKHVLD
Liberal prescription and illegal use of opioids have led to an opioid crisis in the 
United States, and opioid exposure has become the leading cause of death related to 
unintentional injury.64 In previous years, the potential of weak opioids (prescribed 
for postoperative or chronic pain) to cause addiction has been underestimated. 
However, recent studies show that 1–10% of opioid naive patients that have received 
prescription of opioids for postoperative pain become chronic users.65,66 In the study 
E\%UDWLQGXUDWLRQUDWKHUWKDQGRVDJHFRUUHODWHGZLWKPLVXVHHDFKZHHN
and every renewed prescription were associated with an increase in misuse of 
44%.64,GHQWL¿HGULVNIDFWRUVIRUDGGLFWLRQLQFOXGHDJH!\HDUVRIDJHDQGDOVR
young age), female gender, low income, smoking and alcohol use, certain surgical 
procedures, and depression.67 
If a patient needs opioids for postoperative pain at home, follow-up is essential 
to ensure that opioids are not continued beyond the normal healing process and 
addiction does not develop or is treated in time. One of the goals of the Acute 
Pain Service Outpatient Clinics (APS-OPCs) is to ensure that strong opioids are 
not inappropriately continued after recovery. The goal is to provide continuing 
DFWLYHSDLQPDQDJHPHQWDIWHUGLVFKDUJH IURPKRVSLWDOE\HɣHFWLYHPXOWLPRGDO

analgesia so that opioids may be attenuated and in order to prevent chronic pain. 
A patient is referred from a surgical unit to an APS-OPC in a situation where he/
she has severe pain, needs strong opioids and/or large doses of neuropathic pain 
medication at discharge after surgery, there is problematic postoperative pain at 
KRPHRULQFDVHRISURORQJHGQHHGIRUSDLQPHGLFDWLRQ7KH¿UVW$3623&LQWKH
ZRUOGZDVVWDUWHGLQLQ+HOVLQNL8QLYHUVLW\+RVSLWDO)LQODQGDQGD\HDU
IROORZXSVWXG\VKRZHGWKDWDVLJQL¿FDQWQXPEHURIVXUJLFDOSDWLHQWVEHQH¿WHG
$WGLVFKDUJHDIWHUVXUJHU\RISDWLHQWVZHUHXVLQJZHDNRSLRLGVVWURQJ
opioids, and 71% gabapentinoids; at discharge from the APS-OPC, the numbers 
ZHUHDQGUHVSHFWLYHO\DQGRIWKHSDWLHQWVKDGEHHQUHIHUUHG
to the multidisciplinary pain management services for further pain management.68 
7KHPHGLDQWLPHIURPVXUJHU\WRWKH¿UVWFRQWDFWZLWKWKHFOLQLFZDVPRQWKV
WKHPHGLDQGXUDWLRQRIIROORZXSZDVPRQWKV±PRQWKVDQGWKHPHGLDQ
number of contacts was 3 (range 1–14).  
2.4.1. PHARMACOLOGICAL PRINCIPLES 
Pharmacokinetic and pharmacodynamic principles characterize the magnitude and 
WLPHFRXUVHRIGUXJHɣHFW69 Pharmacokinetics describes what the body does to the 
drug—the processes of distribution and elimination (metabolism and excretion). For 
WKHGUXJWRZRUNLWQHHGVWRUHDFKLWVWDUJHWVLWHWDUJHWPROHFXOHDWDVXɤFLHQWO\
high concentration. The increase in concentration and the onset of action depend 
on the pharmacokinetic properties of each drug. Pharmacodynamics describes what 
the drug does to the body, the relationship between drug concentrations and its 
SKDUPDFRORJLFDOHɣHFWWKHPHFKDQLVPVRIDFWLRQDQGELRFKHPLFDODQGSK\VLRORJLFDO
HɣHFWV7KHG\QDPLFUDQJHLVWKHFRQFHQWUDWLRQUDQJHZKHUHWKHGUXJHɣHFWRFFXUV
OHYHOVEHORZWKDWDUH LQHɣHFWLYHDQGWKRVHDERYHWKDWGRQRWSURYLGHDGGLWLRQDO
HɣHFWEXWLQFUHDVHWKHULVNRIDGYHUVHHɣHFWV
,Q¿QGLQJWKHRSWLPDOUHJLPHQDQGGRVHFDUHIXODVVHVVPHQWRIHDFKSDWLHQWV
underlying condition must be recognized: age, body habitus, gender, chronic 
exposure to opioids, benzodiazepines, tobacco or alcohol use, presence of heart, 
lung, kidney, or liver disease, and the extent of blood loss or dehydration. The goal 
is personalized medicine, which in the future will likely make use of the knowledge 
of each patient’s genetic coding for metabolism of analgesics and pain sensitivity. 

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2.4.2. ANALGESICS FOR POST-TONSILLECTOMY PAIN 
2.4.2.1 Paracetamol
Paracetamol is used as the first line analgesic for mild to moderate acute 
SRVWRSHUDWLYHSDLQEXWLQPDQ\FDVHVLWLVLQVXɤFLHQWIRUSDLQFRQWUROZKHQXVHG
alone. It is a safe analgesic in moderate doses; it has minor anti-platelet activity 
and good gastrointestinal tolerance, but the potential for serious hepatic injury 
exists in high doses. Paracetamol is considered a centrally acting analgesic. The 
precise mechanism of action is unknown, and it may deliver analgesia through 
multiple dose-dependent mechanisms. Paracetamol is metabolized into AM404 in 
the liver.71 AM404 is a transient receptor potential vanilloid 1 (TRPV1/capsaicin) 
FKDQQHO LQDFWLYDWRUDQGORZDɤQLW\ OLJDQGRI WKHFDQQDELQRLGUHFHSWRU WKHVH
UHFHSWRUV DUH LQYROYHG LQ WKH DQDOJHVLF HɣHFW RI SDUDFHWDPRO AM404 also 
reduces prostaglandin synthesis in activated microglia (central nervous system 
PDFURSKDJHVE\ LQKLELWLQJF\FORR[\JHQDVH&2;DFWLYLW\ WKLVHɣHFWVHHPVWR
occur in higher paracetamol doses.74 ,WKDVDZHDNDQWLLQÀDPPDWRU\HɣHFWDQG
DGGLWLYHDQDOJHVLFHɣHFWZLWK16$,'V70 Paracetamol has also been suggested to 
modify pain by reinforcing serotonergic descending inhibitory pain pathways.75 
For acute moderate to severe postoperative pain, a single dose of 1 g paracetamol 
RɣHUVDWOHDVWSDLQUHOLHIRYHU±KRXUVIRURIDGXOWSDWLHQWVWKHQXPEHU
needed to treat (NNT) value is 3.5–5 (Figure 4).74 For acute postoperative pain in 
SHGLDWULFSDWLHQWVDVLQJOHGRVHVKRXOGEHDVKLJKDVPJNJí(in hospital 100 
mg kgíGLYLGHGLQGRVHVIRUSRVWRSHUDWLYHGD\VDQGIURPWKHQRQPJNJí 
divided in 3-4 doses).77,78 For fever and pain (other than acute postoperative pain) 
at home, the recommended dose is much lower, 15 mg kg-1 1-3 times daily. For 
adults, the recommended dose is 0.5–1 g p.o. 3 times daily, maximum 3 g daily.  
2.4.2.2. Nonsteroidal anti-inﬂammatory drugs 
16$,'VDUHHɣHFWLYHDQDOJHVLFVWKDWUHOLHYHSDLQDQGLQÀDPPDWLRQEXWWKH\DOVR
KDYHVHULRXVDGYHUVHHɣHFWV16$,'VUHOLHYHSDLQE\LQKLELWLQJWKHDFWLYLW\RI&2;
enzymes and the subsequent production of prostanoids, which are released in 
UHVSRQVH WRQRFLFHSWLRQ VXUJLFDO WUDXPDDQG LQÀDPPDWLRQ3URVWDJODQGLQ(
DQGSURVWDF\FOLQ3*,VHQVLWL]HSDLQQHUYHWHUPLQDOV WRSDLQFDXVHGE\RWKHU
LQÀDPPDWRU\PHGLDWRUVVXFKDVEUDG\NLQLQDQG+7DQGSK\VLFDODJHQWV
There are at least two types of cyclooxygenase (COX) enzymes. The prostaglandins 
produced by the COX-1 enzyme are involved in the regulation of physiological events, 
for example platelets, endothelium, gastric mucosa, and kidney (e.g., thromboxane; 
SODWHOHWDJJUHJDWLQJHɣHFWSURVWDF\FOLQYDVRGLODWRUHɣHFWDQGSODWHOHWDJJUHJDWLRQ

LQKLELWLRQDQG3*(JDVWULFPXFRVDOSURWHFWLYHHɣHFW&2;DOVRKDVSK\VLRORJLFDO
functions (e.g., production of vasodilator and platelet aggregation inhibiting 
SURVWDF\FOLQ3*,LQWKHHQGRWKHOLXPEXWLWLVPDLQO\LQGXFHGLQUHVSRQVHWR
LQÀDPPDWLRQFHUWDLQF\WRNLQHVDQGVWURQJQRFLFHSWLYHVWLPXODWLRQZKLFKWKHQ
results in intense prostanoid synthesis.
7UDGLWLRQDOQRQVHOHFWLYH16$,'VLQKLELWERWK&2;DQG&2;HQ]\PHV7KH
inhibition of COX-1 prevents platelet aggregation and vasoconstriction prolonging 
bleeding time, which may increase postoperative bleeding (depending on the drug 
dose, serum level, and half-life).79%\VHOHFWLYHEORFNLQJRIWKH&2;HQ]\PHWKH
DLPLVWRFDOPLQÀDPPDWLRQDQGUHODWHGSDLQZLWKRXWDɣHFWLQJQRUPDOSURVWDQRLG
PHGLDWHGIXQFWLRQV LQWKHERG\&2;VHOHFWLYH16$,'VGRQRW LQWHUIHUHZLWK
SODWHOHW IXQFWLRQDQGWKXVGRQRWDɣHFWWKHULVNRIEOHHGLQJZLWKUHFRPPHQGHG
doses. However, in the endothelium, vasodilator and platelet aggregation inhibiting 
SURVWDF\FOLQ3*,SURGXFWLRQLVEORFNHGZKLFKPD\LQFUHDVHDUWHULDOWKURPERVLVIRU
H[DPSOHULVNRIVWURNHDQGP\RFDUGLDOLQIDUFWLRQ7KLVDGYHUVHHɣHFWZDVQRWLFHGRYHU
WKH\HDUVDQGVHYHUDO&2;LQKLELWRUVZHUHWDNHQRɣWKHPDUNHW80 Tonsillectomy 
patients are usually healthy and young, without risk of cardiovascular complications, 
DQGWKHUHIRUH&2;LQKLELWRUVDUHXVXDOO\VXLWDEOH,QWKH6ZHGLVKJXLGHOLQHV
&2;LQKLELWRUVDUHDSUHIHUUHGFKRLFHIRUSHGLDWULFSDWLHQWVDQGDOWKRXJKWKH\
are not registered for children, they (mainly celecoxib) have been used clinically for 
many years in the major Swedish pediatric departments without problems.81 Other 
DGYHUVHHɣHFWVRI16$,'VDUHJDVWURLQWHVWLQDOLUULWDWLRQJDVWULFXOFHUSURYRFDWLRQ
anuria and hyperkalemia (in patients with renal disease, congestive heart failure, 
JHQHUDOL]HGDUWHULRVFOHURVLVRUÀXLGLPEDODQFHDQGULVNRIKHDUWIDLOXUHLQFUHDVHGE\
10-fold in patients with cardiac disease). Contraindications include treatment with 
DQWLFRDJXODQWVNLGQH\GH¿FLHQF\JDVWULFXOFHUVHYHUHK\SHUWHQVLRQKHDUWIDLOXUH
UHODWLYHFRQWUDLQGLFDWLRQVDUHDJH!\HDUVDQGFRURQDU\DUWHULDOGLVHDVH&HOHFR[LE
LVFRQWUDLQGLFDWHGIRUSDWLHQWVZLWKVXOIDDOOHUJ\GXHWRLWVVXOSKRQDPLGHVWUXFWXUH
The relationship between NSAIDs and the risk of PTH has been studied over the 
\HDUVZLWKFRQÀLFWLQJUHVXOWV²VRPHV\VWHPDWLFUHYLHZVKDYHUHSRUWHGDQLQFUHDVHG
ULVNRIUHRSHUDWLRQDQGVRPHKDYHQRWIRXQGGLɣHUHQFHV8-10 The latest Cochrane 
UHYLHZRQSHGLDWULFWRQVLOOHFWRP\FRQFOXGHGWKDWLQVXɤFLHQWGDWDH[LVWWR
exclude an increased risk of PTH; the use of traditional NSAIDs was associated with 
DQRQVLJQL¿FDQWO\LQFUHDVHGULVNRIUHRSHUDWLRQ10 In recent pediatric guidelines, 
NSAIDs have been recommended to be used in moderate doses; patients need 
DQDOJHVLDWREHDEOHWRHDWDQGGULQNDQGSDUDFHWDPROLVQRWHɣHFWLYHHQRXJKDV
a single drug.
1RQVHOHFWLYH16$,'VDQG&2;LQKLELWRUVKDYH117YDOXHVUDQJLQJIURP
1.5 to 4.5 (Figure 4). Individual studies on adult tonsillectomies have proved their 
HɤFDF\KRZHYHUQRV\VWHPDWLFUHYLHZKDVEHHQSHUIRUPHGEHIRUHWKDWLQ6WXG\
III. Studies on pediatric tonsillectomy patients have shown that NSAIDs combined 
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ZLWKSDUDFHWDPRODUHDVHɤFLHQWDVRSLRLGVFRPELQHGZLWKSDUDFHWDPRODWSURYLGLQJ
adequate analgesia after tonsillectomy. In Finland, available traditional non-
selective NSAIDs on the market are diclofenac, indomethacin, ketorolac, ibuprofen, 
NHWRSURIHQDQGQDSUR[HQ2IWKH&2;LQKLELWRUVWKUHHDUHDYDLODEOHHWRULFR[LE
and celecoxib, and parecoxib for intravenous (i.v.) use only. 
2.4.2.3. Opioids
Opioids relieve pain by inhibiting opioid receptors in the spinal cord, middle brain, 
EUDLQVWHPFRUWH[DQGYLDSHULSKHUDORSLRLGUHFHSWRUVDFWLYDWHGE\LQÀDPPDWLRQ
2SLRLGVDUHWKHPRVWHɣHFWLYHDQWLQRFLFHSWLYHDJHQWZKLFKFDQEHDGPLQLVWHUHG
by i.v., peroral (p.o.), subcutaneous, transdermal, or transmucosal routes, or as 
additives in regional anesthesia. Optimal analgesia can be achieved easily in hospital 
by titration of strong opioids such as morphine, oxycodone, and fentanyl. The weak 
opioids codeine and tramadol are used for the treatment of moderate to severe 
SDLQ+RZHYHUDGYHUVHHɣHFWVVXFKDV UHVSLUDWRU\GHSUHVVLRQQDXVHDXULQDU\
retention, constipation, ileus, and pruritus may prevent their use. Contraindications 
include severe bronco-pulmonary and neuromuscular diseases. Opioid antagonists 
QDOR[RQHPJNJ-1 LYHYHU\PLQXWHVXQWLOUHVSRQVHLVDFKLHYHGFDQ
WUHDWDOORSLRLGUHFHSWRUPHGLDWHGVLGHHɣHFWVVXFKDVUHVSLUDWRU\GHSUHVVLRQDQG
LWFKLQJ1HXUROHSWLFVHJGHK\GUREHQ]SHULGROPJLYRULPDUHPRVWHɣHFWLYH
in treating nausea, which also aim in opioid-induced confusion. Opioids increase 
reuptake of serotonin in synapses thus increasing risk for serotonin syndrome in case 
of concomitant use of serotonergic medications (SSRI and SNRI antidepressants, 
triptans, 5-HT3 blockers). 
Codeine is a prodrug of which 6–10% is metabolized through the cytochrome 
&<3' HQ]\PH LQWRPRUSKLQH ZKLFK SURYLGHV LWV SULPDU\ DQDOJHVLF HɣHFW
Codeine is mostly used as a combination of 30 mg codeine and 500 mg paracetamol 
(Panacod®, Paramax-Cod®, Paracetamol-Codein®, Altermol®). The combination 
RI±PJSDUDFHWDPROSOXVPJFRGHLQHSRSURYLGHVHɣHFWLYHSDLQUHOLHI
IRUDFXWHSRVWRSHUDWLYHSDLQZLWKDQ117YDOXHRI)LJXUH7KHPD[LPXP
GDLO\GRVHRIFRGHLQHLVPJSRIRUDGXOWV
Pain relief can be inadequate in individuals that carry inactive copies of the 
&<3'JHQHVDQGFRGHLQHLVQRWWUDQVIRUPHGLQWRPRUSKLQH±RI&DXFDVLDQ
people).86 Individuals that have an “ultrafast metabolism” have more than two 
QRUPDOFRSLHVRI&<3'JHQHVDQGLQWKHVHLQGLYLGXDOVFRGHLQHLVUDSLGO\FRQYHUWHG
into morphine and signs of opioid toxicity such as respiratory depression may 
develop. Reports have been published that codeine given postoperatively has led 
to overdoses and deaths in pediatric tonsillectomy or adenotonsillectomy due to OSA 
syndrome, and the majority of these patients have been diagnosed with ultrafast 

PHWDEROL]DWLRQRI&<3'87 Airway swelling after tonsil and/or adenoid surgery 
has been thought to be a contributory risk factor for the development of respiratory 
failure in pediatric sleep apnea patients, whose symptoms worsen immediately 
after surgery.86 Simultaneously occurring opioid sensitivity induced by repetitive 
hypoxic periods, and decreased responsiveness to an increased partial pressure 
of carbon dioxide in the blood, predispose these patients to the risk of respiratory 
GHSUHVVLRQ,IDSDWLHQWLVDOVRD&<3'XOWUDIDVWPHWDEROL]HUWKHUHLVDUHDOGDQJHU
RIUHVSLUDWRU\DUUHVW7KHUHIRUH WKH86)RRGDQG'UXJ$GPLQLVWUDWLRQ LQ
and the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment 
&RPPLWWHH LQUHFRPPHQGHGDYRLGLQJFRQWUDLQGLFDWHFRGHLQHLQFKLOGUHQ
\RXQJHUWKDQ\HDUVUHJDUGOHVVRIWKHVXUJHU\DQGXSWRWKHDJHRI\HDUVLQ
patients undergoing tonsillectomy or adenotonsillectomy for OSA syndrome.
Codeine is also contraindicated for patients with biliary tract disease and acute 
asthma attack (may cause spasm of smooth muscle).  
Tramadol has multiple mechanisms of action, including inhibition of the reuptake 
of serotonin (5-HT) and norepinephrine, and it stimulates the release of serotonin 
from presynaptic nerve terminals. The main active metabolite O-desmethyltramadol 
0ZKLFKLVSURGXFHGE\WKH&<3'HQ]\PHELQGVZLWKUHODWLYHO\KLJKDɤQLW\
WRWKHRSLRLGUHFHSWRU7KXVRSLRLGHɣHFWVRIWUDPDGRODUHODUJHO\LQÀXHQFHGE\
&<3'DFWLYLW\DQGWKLV LVVLPLODUZLWKFRGHLQH)ROORZLQJFRQWUDLQGLFDWLRQRI
codeine for pediatric tonsillectomy patients, tramadol use has increased, causing an 
increasing number of reports on opioid toxicity. In the United States, tramadol is 
DOVRFRQWUDLQGLFDWHGVLQFHIRUFKLOGUHQOHVVWKDQ\HDUVUHJDUGOHVVRIVXUJHU\
and in children less than 18 years after ear, nose, and throat surgery. 
In Europe, tramadol is approved for use in children over 1–3 years for moderate 
to severe nociceptive pain management. The EMA and the European Society for 
Paediatric Anaesthesiology (ESPA) recommend restricting the use of tramadol for 
postoperative pain management in children with OSA syndrome and compromised 
respiratory function. ESPA guidelines nevertheless allow the use of tramadol for 
adenotonsillectomy inpatients if pain is severe despite the use of non-opioids, in 
ZKLFKFDVHDSSURSULDWHPLQLPDOHɣHFWLYHGRVDJHPXVWEHGHWHUPLQHGLQGLYLGXDOO\
by titration in the hospital setting where adequate monitoring is available (usually 
a maximum of 1 mg kgí 1–3 times daily as needed). In order to determinate the 
JHQRW\SHIRUWUDPDGROPHWDEROLVPD&<3'JHQHWHVWFDQEHSHUIRUPHG)RUDGXOWV
the recommended dose is 50–100 mg p.o. 3–4 times daily. In our clinic, tramadol 
LQPRGHUDWHGRVHVLVXVHGIRUDGXOWSDWLHQWVZLWKPLOG26$$+,$GYHUVH
HɣHFWVRIWUDPDGROLQFOXGHGL]]LQHVVGURZVLQHVVVZHDWLQJQDXVHDYRPLWLQJGU\
mouth, and headache, which are more common and harmful for the elderly (overall 
LQFLGHQFHRIWR'XHWRVLPLODUPHFKDQLVPVRIDFWLRQDQG&<3'
mediated pharmacokinetic interactions, the use of tramadol with antidepressants 
should be carefully considered. 
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2.4.3. ADJUVANTS
2.4.3.1. Dexamethasone 
The action of glucocorticoids is mediated through a cytoplasmic receptor. The 
DFWLYDWHGJOXFRFRUWLFRLGUHFHSWRUFRPSOH[DɣHFWVWKHH[SUHVVLRQRIPDQ\JHQHV
either by increasing or decreasing protein synthesis in cells.67 Glucocorticoids 
UHGXFH WKH SURGXFWLRQ RI VHYHUDO LQÀDPPDWRU\ IDFWRUV DQG DW WKH VDPH WLPH
LQFUHDVH WKHV\QWKHVLVRIDQWLLQÀDPPDWRU\ IDFWRUVZKLFKVXSSUHVVHVERWKWKH
DFXWHLQÀDPPDWRU\UHVSRQVHDQGWKHKXPRUDODQGFHOOPHGLDWHGLPPXQHUHVSRQVH
DQGOHDGVWRWKHVXSSUHVVLRQRIWKHLQÀDPPDWLRQ67 Glucocorticoids, particularly 
dexamethasone, are commonly used to reduce pain and PONV.89,90 Without PONV 
prophylaxis, the incidence is 35–75% in pediatric tonsillectomy.87 A single dose 
of dexamethasone intraoperatively decreases postoperative pain, the need for 
rescue opioids, and PONV. A commonly used dose is 0.1–0.15 mg kgí i.v. at 
the induction of anesthesia. An increased risk of PTH associated with the use of 
dexamethasone has been suspected in some small studies, but it has not been 
FRQ¿UPHGLQV\VWHPDWLFUHYLHZVDQGPHWDDQDO\VHVDOWKRXJKDUHFHQWV\VWHPDWLF
review and register study reported an increased risk of reoperation among pediatric 
patients but not among adults.15-18 Several guidelines recommend its use in children 
LQPRGHUDWHGRVHVEDVHGRQEHQH¿WRYHUKDUPLQFOXGLQJGHFUHDVHGWKURDWSDLQ
decreased PONV, and earlier resumption of oral intake, which is crucial in terms 
of hydration, especially when NSAIDs are used.6,81
2.4.3.2. Gabapentinoids
*DEDSHQWLQRLGVJDEDSHQWLQDQGSUHJDEDOLQDFWE\ELQGLQJWRĮįDQGĮįVXEXQLWV
of the voltage-gated Ca++ channel in the presynaptic nerve terminals, inhibiting 
release of excitatory neurotransmitters, controlling the irritability of dorsal horn 
neurons and thus relieving and preventing the development of hyperalgesia. 
Gabapentinoids administered prior to surgery reduce postoperative pain, opioid 
UHTXLUHPHQWVDQGRSLRLGUHODWHGDGYHUVHHɣHFWV$GYHUVHHYHQWVRIJDEDSHQWLQRLGV
such as sedation and dizziness are observed in higher doses, but they are considered 
of minor importance in the case of intense pain in a postoperative setting. Recent 
V\VWHPDWLFUHYLHZVKRZHYHUKDYHTXHVWLRQHGWKHLUHɤFDF\117KDVLQFUHDVHGIURP
±WR±93,94 The disadvantage of gabapentinoids is the potential for misuse and 
addiction. Therefore, treatment decisions should be made on an individual basis. 
In the Helsinki University Hospital, if the type of surgery involves a high risk of 
FKURQLFSDLQRUQHUYHGDPDJHSUHJDEDOLQPJWLPHVGDLO\VWDUWLQJLQWKH

PRUQLQJEHIRUHVXUJHU\DQGFRQWLQXHGIRUZHHNVLVUHFRPPHQGHG3UHJDEDOLQ
LVHOLPLQDWHGE\WKHNLGQH\VDQGLQFDVHRIUHQDOLQVXɤFLHQF\GRVHVPXVWEHORZHU
2.4.3.3. NMDA antagonists 
Ketamine is an anesthetic drug that has been used as a general anesthetic from 
the 1970s, and in recent years in low doses as an adjuvant to analgesia. It causes 
a non-competitive dose-dependent blockade of the NMDA receptor and thereby 
inhibits development of central sensitization and hyperalgesia.63 Low dose ketamine 
as boluses or infusion reduces postoperative pain.55,95,96 In pediatric tonsillectomies, 
DV\VWHPDWLFUHYLHZDQGVWXGLHVSXEOLVKHGWKHUHDIWHUKDYHUHSRUWHGWKDW
SUHRSHUDWLYHLYDQGSHULWRQVLOODUNHWDPLQHORFDOO\SURYLGHSDLQUHOLHIIRUKRXUV
ZLWKRXWDQLQFUHDVHLQVLGHHɣHFWV97
Ketamine is used perioperatively in surgeries in which there is high risk for severe 
postoperative pain. The usual dose of esketamine (s - enantiomer of ketamine) 
LVPJLYEROXVDWWKH LQGXFWLRQRIDQHVWKHVLD IROORZHGE\PJK-1 i.v. 
infusion (1 mg ml-1) until the end of surgery, or continued into PACU. Postoperatively, 
LIRSLRLGVKDYHQRWEHHQHɣHFWLYHHQRXJKDQG WROHUDQFHDQGK\SHUDOJHVLDKDYH
GHYHORSHGHVNHWDPLQHPJLYEROXVUHSHDWHGHYHU\PLQXWHVRU
mg p.o. 4-6 times daily mixed in juice (causes sores, erosion of enamel and tooth 
GHFD\LVXVHIXO.HWDPLQHPD\FDXVHDGYHUVHHɣHFWVVXFKDVLQFUHDVHGVDOLYDWLRQ
hallucinations, nightmares, nausea and vomiting, but in low doses for treatment 
RISDLQDGYHUVHHɣHFWVKDYHQRWEHHQSUREOHPDWLF&HQWUDOQHUYRXVV\VWHPDGYHUVH
reactions may be reduced/prevented by combining ketamine with a small dose 
RIDEHQ]RGLD]HSLQHVXFKDVGLD]HSDPRUPLGD]RODPRUDQDOSKDDJRQLVWVXFK
as clonidine or dexmedetomidine. Ketamine is contraindicated for patients for 
whom there is a serious risk of an increase in blood or cerebral pressure and with 
psychiatric disorders. 
Dextromethorphan has been studied in recent years for adjuvant to opioid 
analgesia. It has been used an over-the-counter anti-tussive drug for decades. 
Dextromethorphan is an NMDA-receptor antagonist and has also many other 
neuropharmacological actions—among others, it increases serotonin levels in 
V\QDSVHV,WLVPHWDEROL]HGE\WKH&<3'HQ]\PH$TXDOLWDWLYHV\VWHPDWLFUHYLHZ
RISHULRSHUDWLYHGH[WURPHWKRUSKDQIRUSRVWRSHUDWLYHSDLQLQFOXGLQJVWXGLHVRI
which three were tonsillectomy studies, reported a reduced need for opioids and 
a reduction in opioid-related adverse events especially when used parenterally, 
EXWFOLQLFDOPHDQLQJIXOQHVVRIWKHHɣHFWZDVQRWFOHDU98 In a more recent meta-
analysis that included 40 studies of which two were tonsillectomy, perioperative 
GH[WURPHWKRUSKDQZDVDVVRFLDWHGZLWKDVLJQL¿FDQWUHGXFWLRQLQSDLQVFRUHVDQG
SRVWRSHUDWLYHRSLRLGXVHIRU±KRXUVIROORZLQJVXUJHU\99 
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2.4.3.4. Other adjuvants
Antihyperalgesic adjuvants magnesium, dexmedetomidine, and lidocaine as i.v. 
infusions are increasingly used and studied as part of multimodal analgesia in 
many surgical procedures.100 So far, for post-tonsillectomy pain, the evidence of 
HɤFDF\KDVEHHQPLQLPDORUQRQH[LVWHQW101 Magnesium is a weak NMDA antagonist 
which has been shown to reduce postoperative analgesic consumption and opioid-
UHODWHGDGYHUVHHɣHFWVLQRUWKRSHGLFVXUJHU\ZKHQDGPLQLVWHUHGDVLYLQIXVLRQ 
'H[PHGHWRPLGLQHLVDVHOHFWLYHĮDJRQLVWVZLWKDQDOJHVLFVHGDWLYHDQ[LRO\WLFDQG
V\PSDWKRO\WLFHɣHFWV101,WSRWHQWLDWHVWKHHɣHFWRIRSLRLGVV\QHUJLVWLFLQWHUDFWLRQ
DQGSRVVLEO\GHYHORSPHQWRIWROHUDQFH6\PSDWKRO\WLFHɣHFWUHVXOWVIURPGHFUHDVHG
release of norepinephrine from sympathetic nerve endings. In addition to its 
DQDOJHVLFHɣHFWVGH[PHGHWRPLGLQHLVFRPPRQO\XVHGDVDVHGDWLYHLQWKHLQWHQVLYH
FDUHXQLWIRUDZDNHWUDFKHDOLQWXEDWLRQZLWK¿EHUVFRSHDQGQDVDOO\DGPLQLVWHUHG
in sedation for minor operations especially in pediatric patients. Bradycardia 
LVDFRPPRQDGYHUVHHɣHFWDQGWKHUHIRUHPRQLWRULQJ LVQHHGHG/LGRFDLQH LVD
common local anesthetic and antiarrthymic drug which has been used in recent 
years as intravenous infusion for prevention of hyperalgesia and postoperative 
pain.55, 103 $FFRUGLQJWRUHFHQW&RFKUDQHUHYLHZRQFRQWLQXRXVLQWUDYHQRXV
perioperative lidocaine infusion for postoperative pain and recovery in adults, 
FOLQLFDOO\UHOHYDQWHɣHFWZDVTXHVWLRQDEOHODWHUWKDQKRXUV103 
Analgesics and adjuvants for acute postoperative pain are listed in Table 1. 
Recommendation of post-tonsillectomy pain medication in adult and pediatric 
outpatients at the Helsinki University Hospital, Department of Otorhinolaryngology—
+HDGDQG1HFN6XUJHU\DUHIRXQGLQ$SSHQGL[DQGUHVSHFWLYHO\
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Table 1. Analgesics and adjuvants for acute postoperative pain. AV, atrioventricular; CNS, central nervous system; COX, cyclooxygenase; 
i.v., intravenous; NMDA, N-methyl-D-aspartate; OSA, obstructive sleep apnea; PACU, post-anesthesia care unit; p.o., perorally.  
Analgesics, 
adjuvants Mechanism of action
Usual dose in acute 
postoperative pain Adverse effects Contraindications
Paracetamol Metabolism to AM404 ń inhibition 
of COX in CNS ń production of 
prostaglandins Ļ
TRPV1/capsaicin channel 
inactivation
Cannabinoid-1 receptor activation
Serotonergic descending inhibitory 
pain pathways?
Adults: 0.5–1g x 1–3 p.o. /day
Pediatric:
100 mg/kg p.o. /day for 2 
days, followed by 60 mg/
kg p.o. /day (divided in 3–4 
doses) 
Potential for serious hepatic injury 
in high single doses > 150/mg/kg
Liver insufficiency 
Do not combine with NSAIDs in 
longstanding use (risk of kidney 
failure)
NSAIDs
- Traditional: 
Diclofenac, 
indomethacin, 
ketorolac, 
ibuprofen, 
ketoprofen, 
naproxen
- COX-2  
selective: 
etoricoxib, 
celecoxib, 
parecoxib
Inhibition of cyclo oxygenase 
enzymes (COX) ń 
production of prostaglandins Ņ 
(released in response to 
nociception, surgical trauma, 
inﬂammation)
Adults: Ibuprofen 600–800 
mg x 3 p.o., dexketoprofen 
50mg p.o. x 1–3/day 
Pediatric:
Naproxen 5 mg/kg x 2
Ibuprofen 40 mg/kg/day 
(divided in 3 doses p.o./p.r.)
Celecoxib?
- Gastrointestinal irritation 
and bleeding, gastric ulcer 
provocation
- Anuria and hyperkalemia in 
patients with renal disease, 
congestive heart failure, 
generalized arteriosclerosis or 
ﬂuid imbalance
- In patients with cardiac disease, 
the risk of heart failure 10-fold 
increased
- Anticoagulants
- Asthma (10% of patients)
- Kidney deﬁciency
- Gastric ulcer
- Cardiovascular disease 
(depending on severity), 
generalized arterio-sclerosis
- Fluid imbalance
- Age above 70–75 years 
(relative)
Opioids: 
Oxycodone, codeine, 
tramadol
Opioid receptors 
(ȝ, į, and ț) 
- in spinal cord, middle brain, 
brainstem and cortex
- peripheral opioid receptors 
activated by inﬂammation
Adults:
- Oxycodone 0.05mg/kg 
i.v., 0.07-0.13 mg/kg i.m., 
5–15mg p.o., 30–50% less 
for elderly 
- Tramadol 50-100mg p.o. x 
1-3/day
- Paracetamol 500mg-
codeine 30mg p.o. 1–2 x 
3–4/day
Pediatric: Oxycodone 0.05–
0.1 mg/kg i.v., tramadol 1–2 
mg/kg p.o. x 1-4/day
All:
- Respiratory depression 
(dose-dependent), PONV, 
urinary retention, constipation, 
ileus, pruritus, addiction, 
endocrinological and 
immunological effects
- Risk of serotonin syndrome with 
SSRI + SNRI antidepressants, 
triptans
Tramadol:
- Dizziness, drowsiness, sweating, 
nausea, vomiting, dry mouth, 
headache
All:
- Severe bronco-pulmonary 
disease
- Neuromuscular diseases
- OSA (except tramadol if AHI < 
15)
Paracetamol-codeine + tramadol: 
- <12 years of age
- 12-18 years of age if 
tonsillectomy for OSA
- CYP2D6 ultra-fast metabolizer
Paracetamol-codeine:
Liver insufficiency, biliary tract 
disease, acute asthma attack
Dexamethasone Glucocorticoid receptor in the 
in the cytoplasm in the cell ĺ 
suppression of inﬂammation Ļ
0.1–0.15 mg/kg i.v. at the 
induction of anesthesia
Elevation of blood glucose level, 
immunosuppression
Caution if diabetes, gastric or 
duodenal ulcer
Gabapentinoids:
Pregabalin, 
gabapentin
Į1į and Į2į-subunits of voltage-
gated Ca++ channel antagonist 
in the presynaptic nerve 
terminals in CNS ĺ excitatory 
neurotransmitters Ļ,
irritability of dorsal horn neurons Ļ,
hyperalgesia Ļ
Pregabalin: 75–150 mg p.o.x2/ 
day for 2–4 weeks e.g. if the 
type of surgery involves a 
high risk of chronic pain or 
nerve damage
Fatigue, drowsiness, dizziness, 
headache, memory and speech 
disorders, paresthesia, ataxia, 
visual disturbances, dyspepsia, 
weight gain, peripheral edema not 
relieved by diuretics, addiction
Allergy
NMDA- 
antagonists:
Ketamine
(dextro methorphan 
under studies)
NMDA receptor antagonist, 
ketamine: hyperalgesia Ļ
Esketamine: 
- At induction of anesthesia 
bolus 10–25 mg i.v. + 
infusion (1mg/ml) 2–5 
mg/h i.v.
- PACU: 1–2.5mg i.v. repeated 
every 5–10 min /+ infusion 
2–5 ml/h (1mg/ml) i.v., or 
25–50 mg p.o. × 4–6/day in 
juice
Ketamine: increased salivation, 
hallucinations, nightmares, nausea 
and vomiting are rare, when used 
in subanesthetic doses for pain
(hallucinations may be reduced/ 
prevented by combining with a 
small dose of a benzodiazepine 
such as diazepam or Į2 agonists).
Tooth decay
Patients for whom there is a 
serious risk of an increase in 
blood or cerebral pressure, 
psychiatric disorders
Magnesium Weak NMDA antagonist, 
hyperalgesia Ļ
i.v. infusion/ locally in regional 
anesthesia
Hypotension Myasthenia gravis severe kidney 
deﬁency
Lidocaine Sodium channel blocker, 
immunosupression, other 
mechanism? At therapeutic plasma 
levels (1–3 mg/l) alleviates various 
pain conditions. Hyperalgesia Ļ
i.v. infusion/ locally in regional 
anesthesia
Hypotension, bradycardia Allergy, many contraindications if 
used as infusion
Į2 agonists:
dexmedetomidine, 
clonidine 
Į2 agonists potentiate the effect 
of opioids (synergistic interaction), 
development of tolerance? 
Sympatholysis  (inhibition of 
norepinephrine release from 
sympathetic nerve endings) 
Hyperalgesia Ļ
i.v. infusion/ locally in regional 
anesthesia
Hypotension, bradycardia AV block, uncontrolled 
hypotension, bradycardia, acute 
cerebrovascular accident

 5HYLHZRIOLWHUDWXUH
Figure 4. Single-dose analgesics for moderate to severe acute pain: NNT for at least 50% maximum pain 
relief over 4–6 hours. NNT, number needed to treat is a measurement of the impact of a medicine or 
therapy by estimating the number of patients that need to be treated in order to have an impact on one 
person. The higher the NNT, the less effective the treatment. Treatments with NNTs of 2–5 are considered 
effective for acute pain. Reproduced with permission from Moore RA, Derry S, Aldington D, Wiffen PJ. 
Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. 
Cochrane Database of Systematic Reviews 2015, 9. Art. No.: CD008659. 
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2.4.4.  LOCAL ANESTHETICS
Local anesthetics provide regional anesthesia by producing a blockade of neuronal 
transmission when applied near the axons. Action potentials are blocked due to 
DQLQKLELWLRQRIVRGLXP1DÀRZWKURXJKWKH1DFKDQQHOE\GLUHFWEORFNLQJRU
LQÀXHQFLQJWKH1DFKDQQHOFRQIRUPDWLRQ104 Local anesthetics are usually weak 
bases (pKa = 7.6–9.0) that are commercially prepared as an acidic solution, typically 
DWS+±WRHQVXUHSUHVHUYDWLRQ7KHS.DGH¿QHVWKHS+ZKHUHKDOIRIWKHGUXJLV
ionized (conjugate acid) and half is non-ionized (base). The non-ionized (base) form 
is more hydrophobic than the ionized form and penetrates the nerve membrane. 
,IWLVVXHLVDFLGLFHJVXUJLFDOVLWHLQÀDPPDWLRQPRVWRIWKHORFDODQHVWKHWLFLV
in its ionized (hydrophilic) form and does not pass through the nerve membrane, 
UHVXOWLQJLQDZHDNHUHɣHFW104 In clinical practice, sodium bicarbonate has been 
added to local anesthetics to increase the pH and the proportion of the membrane-
penetrating lipid soluble form, and found to decrease the onset of the sensory 
EORFNDGHDOWKRXJKWKHPDJQLWXGHRIWKHHɣHFW LVPLQLPDOHSLGXUDODQHVWKHVLD
peribulbar anesthesia).105,106
Local anesthetics (lidocaine, bupivacaine, levobupivacaine, ropivacaine) have 
been studied as peritonsillar injection before tonsillectomy or topically with 
swabs soaked in local anesthetic after removal of tonsils; however, the evidence 
UHJDUGLQJWKHHɤFDF\LVPLQLPDODQGRITXHVWLRQDEOHPHDQLQJIXOQHVV Topical 
anesthesia is considered safer than peritonsillar injection as no needle penetrates 
WLVVXH$GMXYDQWVWRORFDODQHVWKHWLFVLQSHULSKHUDODQGUHJLRQDOQHUYHEORFNVĮ
adrenergic receptor agonists (clonidine, dexmedetomidine), dexamethasone, and 
magnesium have been shown to prolong analgesia.97,107,108 A systematic review of 
DGMXYDQWVWR ORFDODQHVWKHWLFV LQSRVWWRQVLOOHFWRP\SDLQUHSRUWHGVWURQJ
HYLGHQFHUHJDUGLQJWKHHɣHFWRIPDJQHVLXP10'$DQWDJRQLVWWKDWKDVV\QHUJLVWLF
action with local anesthetics) and dexamethasone in the reduction of pain and 
DQDOJHVLFUHTXLUHPHQWRYHUKRXUVDQGUHFRPPHQGHGWKHLUXVH109 Tramadol and 
PHSHULGLQHGLGQRWKDYHDVLPLODUHɣHFWRQSDLQDQGDQDOJHVLD&XUUHQWUHVHDUFKRQ
local anesthetics is now focusing on novel molecules with longer duration of action 
(e.g., butyl-amino-benzoate, an ester local anesthetic agent that has been shown 
to provide pain relief for up to 14 weeks by novel mechanisms such as blockade 
of Na+ and K+ channels), and delivery mechanisms for prolonged bioavailability, 
such as liposomal, microsphere, and cyclodextrin systems, which may provide safer 
perioperative care, and reduced opioid consumption and pain, while minimizing 
VLGHHɣHFWV110
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3. AIMS OF THE STUDY
The main purpose of the present work was to investigate immediate complications 
after tonsillectomy with emphasis on PTH, and the intensity of post-tonsillectomy 
SDLQ,QDGGLWLRQWKHDLPZDVWRHYDOXDWHWKHHYLGHQFHRIWKHHɣHFWLYHQHVVRIV\VWHPLF
analgesics and dexamethasone for post-tonsillectomy pain, and whether topical 
URSLYDFDLQHLVHɣHFWLYHLQWKHSUHYHQWLRQRISRVWWRQVLOOHFWRP\SDLQ
7KHVSHFL¿FDLPVZHUH
1. To investigate the incidence of post-tonsillectomy complications (Studies I and 
II).
 7R LQYHVWLJDWHZKHWKHUSHULRSHUDWLYHPHGLFDWLRQ LVDVVRFLDWHGZLWKULVNRI
complications (Studies I and II).
3. To assess the intensity of post-tonsillectomy pain (Studies III and IV).
 7R HYDOXDWH HYLGHQFH RI WKH DQDOJHVLF HɣHFW RI V\VWHPLF DQDOJHVLFV DQG
dexamethasone (Study III).
 7RLQYHVWLJDWHWKHHɤFDF\RIWRSLFDOURSLYDFDLQHLQSUHYHQWLQJSRVWWRQVLOOHFWRP\
pain (Study IV).
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4. MATERIAL AND METHODS
4.1. PATIENTS
4.1.1. STUDIES I AND II
Studies I and II are retrospective chart reviews that analyzed the incidence of PTH 
in pediatric outpatients (Study I), the incidence of all postoperative complications 
of adult outpatients (Study II), and the association of those complications with 
perioperatively administered medications. Patients were operated for tonsillectomy 
ZLWKRUZLWKRXWDGHQRLGHFWRP\GXULQJDPRQWKSHULRGEHWZHHQ0D\
DQG$SULODWWKH'HSDUWPHQWRI2WRUKLQRODU\QJRORJ\²+HDGDQG1HFN
Surgery, in Helsinki University Hospital. The exclusion criterion was tonsillectomy 
SHUIRUPHGDVSDUWRIDFRPELQHGVXUJLFDOSURFHGXUH,Q6WXG\,DGXOWSDWLHQWV
(16 years or older) were included, and in Study II, 691 pediatric patients (1–16 years).
4.1.2. STUDY III
6WXG\,,,LVDV\VWHPDWLFUHYLHZDQGPHWDDQDO\VLVWKDWHYDOXDWHGHYLGHQFHRIHɤFDF\
DGYHUVHHɣHFWVDQGWKHFOLQLFDOYDOXHRIV\VWHPLFDQDOJHVLFVDQGGH[DPHWKDVRQH
XVHGIRUSRVWWRQVLOOHFWRP\SDLQLQDGXOWDQGDGROHVFHQW\HDUVRIDJHSDWLHQWV
Double-blind placebo-controlled randomized studies were included. Studies of less 
than 10 participants in a group were excluded. Twenty-nine trials representing 1816 
patients met the inclusion criteria (Figure 5).
4.1.3. STUDY IV
6WXG\,9LVDSURVSHFWLYHUDQGRPL]HGGRXEOHEOLQGVWXG\WKDWLQYHVWLJDWHGWKHHɣHFW
of topical 1% ropivacaine on post-tonsillectomy pain in adult outpatient surgery 
patients during two postoperative weeks. 160 adult patients were enrolled, of which 
6 were excluded on the day of surgery for various reasons (Figure 6) and 154 in 
WRWDOZHUH LQFOXGHGLQWKH¿QDODQDO\VLVSDWLHQWV LQWKHVWXG\JURXSDQG
patients in the control group). The inclusion criteria were suitability for an outpatient 
SURFHGXUHDQGFODVVL¿FDWLRQ,WR,,RIWKH$PHULFDQ6RFLHW\RI$QHVWKHVLRORJLVWV
$6$7KHH[FOXVLRQFULWHULDZHUHSHULWRQVLOODUDEVFHVVOHVVWKDQZHHNVEHIRUH
surgery, suspected malignancy of the tonsils, coagulation disorder, regular use of 
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prescription pain medication or antidepressants, contraindications to the drugs on 
the study, inability to communicate in Finnish or Swedish, inability to use a numeric 
rating scale (NRS) to measure pain intensity, and lack of Internet access at home.
4.2. ETHICAL ISSUES
Studies I, II, and IV were approved by the Institutional Ethics Committee. Informed 
consent was obtained from every participant in Study IV before entering the study.
4.3. STUDY DESIGNS, PROTOCOLS, INTERVENTIONS,  
AND OUTCOME MEASURES
4.3.1. STUDIES I AND II
Data on demographics, postoperative diagnosis, operation time, perioperative 
systemic and local medications, and type of postoperative complications were 
FROOHFWHGIURPPHGLFDOUHFRUGVGXULQJDPRQWKSHULRGEHWZHHQ0D\
DQG$SULOLQWKH'HSDUWPHQWRI2WRUKLQRODU\QJRORJ\+HOVLQNL8QLYHUVLW\
+RVSLWDO)LQODQG7KHXVHRISHULWRQVLOODULQ¿OWUDWLRQVRIORFDODQHVWKHWLFOLGRFDLQH
10 mg mlí) containing epinephrine 10 mg mlí and/or packages dipped in bismuth 
subgallate paste (factor XII activator in coagulation cascade) were recorded. 
3RVWRSHUDWLYHEOHHGLQJHSLVRGHVZHUHFODVVL¿HGDFFRUGLQJWRWKHFULWHULDRI:LQGIXKU
and Seehafer: Grade I = stopped spontaneously or after clot removal, Grade II = 
required direct pressure or minor electrocautery under local anesthesia, Grade III 
= reoperation under general anesthesia.111 ,Q6WXG\,,FRPSOLFDWLRQZDVGH¿QHGDV
any unplanned contact with the hospital’s health-care professionals that resulted in 
medical treatment within one month postoperatively. Dehydration was diagnosed 
as reported in the medical record based on the clinical examination and infection 
as empirical antibiotic treatment due to clinical presentation, and pneumonia was 
diagnosed with clinical examination and chest x-ray. In both studies, the incidence 
of complications and their association with perioperative medication was analyzed.
4.3.2. STUDY III
Study III is a systematic review and meta-analysis that followed the PRISMA 
statement guideline in performing and reporting the review (Figure 5). 
Databases were searched to identify published or ongoing trials: PubMed, Ovid 
Medline, Cochrane Library, ClinicalTrials.gov, and EudraCT and by hand searching 
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reference lists of included studies and reviews. Randomized, double-blind, placebo-
FRQWUROOHGVWXGLHVSXEOLVKHGIURP-DQXDU\WR)HEUXDU\UHSRUWLQJRQ
pain intensity or use of rescue analgesia in English were included. The inclusion 
criteria of intervention were administration of systemic analgesics (paracetamol, 
NSAIDs, gabapentin, pregabalin, ketamine, dextromethorphan) or dexamethasone 
for the prevention or treatment of pain. The primary outcome was incidence and/
or intensity of pain and the secondary outcomes were use of rescue analgesia and 
DGYHUVHHɣHFWV7KHPHWKRGRORJLFDOTXDOLW\DQGSRWHQWLDOELDVRILQFOXGHGVWXGLHV
was assessed by the Cochrane risk of bias tool and Oxford Quality Scoring Scale 
RQO\VWXGLHVZLWKDVFRUHZHUHLQFOXGHG113 
ZĞĐŽƌĚƐŽĨƐƚƵĚŝĞƐŝĚĞŶƚŝĨŝĞĚƚŚƌŽƵŐŚ
ĚĂƚĂďĂƐĞƐĞĂƌĐŚŝŶŐ;ŶсϮϮϭϵͿ
ĚĚŝƚŝŽŶĂůĂďƐƚƌĂĐƚƐŝĚĞŶƚŝĨŝĞĚƚŚƌŽƵŐŚŽƚŚĞƌ
ƐŽƵƌĐĞƐ;ƚƌŝĂůƌĞŐŝƐƚƌŝĞƐ͕ƌĞĨĞƌĞŶĐĞůŝƐƚƐͿ;ŶсϭϰͿ
ZĞĐŽƌĚƐŽĨƐƚƵĚŝĞƐĂĨƚĞƌĚƵƉůŝĐĂƚĞƐ
ƌĞŵŽǀĞĚ;ŶсϭϮϮϴͿ
ďƐƚƌĂĐƚƐƐĐƌĞĞŶĞĚ
;ŶсϭϮϰϮͿ
ďƐƚƌĂĐƚƐĞǆĐůƵĚĞĚ
;ŶсϭϭϲϭͿ
&ƵůůͲƚĞǆƚĂƌƚŝĐůĞƐĂƐƐĞƐƐĞĚĨŽƌĞůŝŐŝďŝůŝƚǇ
;ŶсϴϭͿ
&ƵůůͲƚĞǆƚĂƌƚŝĐůĞƐĞǆĐůƵĚĞĚ;ŶсϱϮͿ
EŽƚƉƌŽƐƉĞĐƚŝǀĞ͗ϱ
EŽƚĚŽƵďůĞďůŝŶĚĞĚ͗Ϯ
EŽƚZd͗ϲ
EŽƉůĂĐĞďŽ͗Ϯϭ
WĂƌƚŝĐŝƉĂŶƚƐфϭϬ͗Ϯ
DŝǆĞĚ;ĂĚƵůƚĂŶĚƉĞĚŝĂƚƌŝĐͿ͗ϯ
WĞĚŝĂƚƌŝĐ͗ϭ
EŽƚƉĂŝŶ͗ϲ
>ĞƚƚĞƌ͗ϱ
EŽƚƐǇƐƚĞŵŝĐĂŶĂůŐĞƐŝĐ͗ϭ
^ƚƵĚŝĞƐŝŶĐůƵĚĞĚŝŶƋƵĂůŝƚĂƚŝǀĞƐǇŶƚŚĞƐŝƐ
;ŶсϮϵͿ
^ƚƵĚŝĞƐŝŶĐůƵĚĞĚŝŶƋƵĂŶƚŝƚĂƚŝǀĞ
ƐǇŶƚŚĞƐŝƐ;ŵĞƚĂͲĂŶĂůǇƐŝƐͿ;ŶсϭϯͿ
Figure 5. Flow chart of Study III. RCT, randomized controlled trial.      
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4.3.3. STUDY VI
Study VI is a prospective placebo-controlled randomized study. Patients were 
allocated into two study groups based on computer-generated randomization (Figure 
$VDSUHPHGLFDWLRQDOOSDWLHQWVUHFHLYHGJSDUDFHWDPRODQGLIQHFHVVDU\PJ
diazepam orally. Surgery was performed under standardized general anesthesia. 
Induction was performed with propofol (3–5 mg kgíIHQWDQ\OWDUJHW±J
kgí), and rocuronium (0.3–0.5 mg kgí). Dexamethasone 0.1–0.15 mg kgí i.v. 
PD[LPXPPJDWLQGXFWLRQDQGWURSLVHWURQPJLYDWWKHHQGRIVXUJHU\ZHUH
administered for the prevention of PONV. Tonsillectomy was performed with cold 
instruments and hemostasis with bipolar forceps and compression with swabs. 
$WWKHHQGRIVXUJHU\DIWHUKHPRVWDVLVSDWLHQWVUHFHLYHGNHWRSURIHQ±PJNJí 
i.v. (target 1.5 mg kgí ideal body weight, maximum 100 mg) for the prevention 
RISRVWRSHUDWLYHSDLQ$QXUVHXQDɤOLDWHGZLWKWKHVWXG\SUHSDUHGDV\ULQJHZLWK
either ropivacaine (Naropin®, B. Braun) or NaCl 0.9% according to the computer-
generated randomization list made by a pharmacist at the hospital pharmacy. Liquid 
was then injected into a sterile steel cup containing four small swabs, which were 
WKHQVTXHH]HGWRUHPRYHH[FHVVÀXLG$WWKHHQGRIVXUJHU\WZRVZDEVZHUHWLJKWO\
packed into each tonsillar bed for 5 minutes.
3RVWRSHUDWLYHSDLQLQWHQVLW\XVLQJ156UDQJH±DQGDGYHUVHHɣHFWVZHUH
recorded every 10 minutes in the post-anesthesia care unit (PACU) and at the 
Outpatient Surgery Unit every hour until discharge. If pain was measured at 
UHVW156U!RURQVZDOORZLQJ156V!R[\FRGRQHPJNJí i.v.) was 
administered as a rescue analgesic in the PACU, or one tablet of a combination of 
paracetamol (500 mg) and codeine (30 mg) (Panacod®) in the Outpatient Surgery 
Unit. At discharge, patients received 600 mg tablets of ibuprofen to be used 3 times 
GDLO\UHJXODUO\GXULQJWKH¿UVWZHHNDQGWKHUHDIWHUDVQHHGHGIRUZHHNVDQGRQH
RUWZRWDEOHWVRI3DQDFRG±WLPHVGDLO\GXULQJWKH¿UVW±SRVWRSHUDWLYHGD\V
DQGWKHUHDIWHUDVQHHGHGIRUZHHNV)RUZHHNVSDWLHQWVFRPSOHWHGDVHFXUHGZHE
based electronic questionnaire every day on intensity of pain and other symptoms 
IURPWKHSUHYLRXVKRXUV $SSHQGL['DWDRQSDWLHQWDJHZHLJKWKHLJKW
VPRNLQJ$6$FODVVL¿FDWLRQSRVWRSHUDWLYH156VDQG156UYDOXHVUHVFXHDQDOJHVLD
and adverse events during the perioperative period, and postoperative complications 
ZHUHFROOHFWHGIURPHDFKSDWLHQW¶VPHGLFDOUHFRUGV%OHHGLQJHSLVRGHVZHUHFODVVL¿HG
according to the criteria proposed by Windfuhr and Seehafer.111 
The primary outcome was NRS on swallowing (NRSs) on postoperative days 
±7KHVHFRQGDU\HQGSRLQWVZHUHZRUVWSDLQGXULQJWKHKRXUIROORZXSLQWKH
PACU, NRSs and NRSr during the second postoperative week, and the number of 
LEXSURIHQDQGSDUDFHWDPROFRGHLQHWDEOHWVFRQVXPHGGXULQJWKHZHHNIROORZXS
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/RVWWRIROORZXSDQVZHUHGRQO\RQOLPLWHGQXPEHU
RIGD\VGXULQJQGZHHNQ 
,QWHUYHQWLRQGLVFRQWLQXHGPHGLFDWLRQPRGLILHGGXH
WR3219Q 
/RVWWRIROORZXSDQVZHUHGRQO\RQOLPLWHGQXPEHU
RIGD\VGXULQJQGZHHNQ 
,QWHUYHQWLRQGLVFRQWLQXHGPHGLFDWLRQPRGLILHGGXH
WR3219Q 
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$VVHVVHGIRUHOLJLELOLW\Q 
([FOXGHGQ 
)DLOHGWRPHHWLQFOXVLRQFULWHULDQ 
'HFOLQHGWRSDUWLFLSDWHQ RWKHU
UHDVRQVQ 
$QDO\]HGQ SRG
([FOXGHGIURPDQDO\VLVLQFRUUHFWSDLQPHGLFDWLRQ
LEXSURIHQGRVDJHWRRKLJKQ 
/RVWWRIROORZXSDQVZHUHGRQO\RQOLPLWHGQXPEHU
RIGD\VGXULQJVWZHHNQ QRUHVSRQVHGXHWR
LQFRUUHFWHPDLODGGUHVVQ Q 
$OORFDWHGWRLQWHUYHQWLRQ5RSLYDFDLQHQ 
5HFHLYHGDVVLJQHGLQWHUYHQWLRQQ 
'LGQRWUHFHLYHDVVLJQHGLQWHUYHQWLRQLQFRUUHFW
ORFDODQDHVWKHWLFQ 
/RVWWRIROORZXSDQVZHUHGRQO\RQOLPLWHGQXPEHU
RIGD\VGXULQJVWZHHNQ QRUHVSRQVHQ 
Q 
$OORFDWHGWRLQWHUYHQWLRQ&RQWUROQ 
5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ 
'LGQRWUHFHLYHDOORFDWHGLQWHUYHQWLRQ
DQDSK\ODFWLFUHDFWLRQDWWKHLQGXFWLRQQ 
$QDO\]HGQ SRG
([FOXGHGIURPDQDO\VLVLQFRUUHFWSDLQPHGLFDWLRQ
LEXSURIHQGRVDJHWRRKLJKQ 
5DQGRPL]HGQ 
$QDO\]HGQ SRG
([FOXGHGIURPDQDO\VLVEOHHGLQJSULRUWRH[WXEDWLRQ
Q 
$QDO\]HGQ SRG
([FOXGHGIURPDQDO\VLVSHULRSHUDWLYHEOHHGLQJ
WUDFKHDOVSDVPDQGUHLQWXEDWLRQPLVVLQJ
LQIRUPDWLRQQ 
$QDO\]HGQ SRG
([FOXGHGIURPDQDO\VLVLQFRUUHFWSDLQPHGLFDWLRQ
LEXSURIHQGRVDJHWRRKLJKQ 

$QDO\]HGQ SRG
([FOXGHGIURPDQDO\VLVLQFRUUHFWSDLQPHGLFDWLRQ
LEXSURIHQGRVDJHWRRKLJKQ GLIIHUHQW16$,'
Q Q 
Figure 6. Flow chart of Study IV. NSAID, nonsteroidal anti-inﬂammatory drug; Pod; postoperative day; 
PONV, postoperative nausea and vomiting.     
4.4. STATISTICS
4.4.1. STATISTICAL METHODS
In Studies I, II, and III, continuous data were presented as the median with standard 
GHYLDWLRQ6'DQGFRQ¿GHQFHLQWHUYDO&,DQGLQ6WXG\,9DVWKHPHGLDQ
with interquartile range (IQR) and 95% CI, and categorical data as mean with range. 
Continuous data were analyzed by performing statistical analyses with the Mann–
Whitney UWHVWDQGFDWHJRULFDOGDWDE\WKH3HDUVRQǒWHVWLQDOOVWXGLHV6WDWLVWLFDO
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VLJQL¿FDQFHZDVVHWDWDSYDOXHRIDQGWKH%RQIHUURQLFRUUHFWLRQZDVXVHG
for adjustment of the p value in the multiple comparison situation (Study IV).
Study I investigated the incidence of PTH, and Study II the incidence of 
all postoperative complications. Both studies investigated the association of 
complications with perioperative medication, reported as the odds ratio (OR) 
ZLWK&,:HXVHG,%063666WDWLVWLFVWRSHUIRUPVWDWLVWLFDODQDO\VLVDQG
&RQ¿GHQFHLQWHUYDODQDO\VLVVRIWZDUHY7UHYRU%U\DQW/RQGRQ8.IRUWKH
&,OLPLWRIGLɣHUHQFH0XOWLFROOLQHDULW\DQGFRQIRXQGLQJIDFWRUVZHUHDQDO\]HGZLWK
regression analysis (Study II).
In Study III data were analyzed quantitatively in a meta-analysis when a 
JURXSRIVWXGLHV LQZKLFKFOLQLFDOKHWHURJHQHLW\ZDVVXɤFLHQWO\VPDOOFRXOGEH
LGHQWL¿HG0HWDDQDO\VLVZDVFDUULHGRXWZLWK5HYLHZ0DQDJHU5HY0DQY
&RSHQKDJHQ7KH1RUGLF&RFKUDQH&HQWUH7KH&RFKUDQH&ROODERUDWLRQ
If clinical heterogeneity was too great, data were analyzed qualitatively. We used 
“no more than mild pain” (less than 3/10 on the pain scale) as an acceptable result 
in clinical practice.114
In Study IV, area under curve (AUC) was plotted for the daily NRS values for 
each patient during the follow-up time (single value per patient) and compared 
EHWZHHQJURXSVWRDVVHVVWKHWUHDWPHQWHɣHFWUHÀHFWLQJSDLQEXUGHQEHWWHUWKDQ
VLQJOHYDOXHVRIJURXSVSHUGD\:HPHDVXUHGDGYHUVHHɣHFWVGXULQJWKHIROORZXSRI
1–14 days postoperatively (questionnaires), also expressed as AUC. We used NCSS 
ZZZQFVVFRPIRUVWDWLVWLFDODQDO\VHV&RQ¿GHQFHLQWHUYDODQDO\VLVVRIWZDUHY
IRUWKH&,OLPLWRIGLɣHUHQFHDQGWKHHOHFWURQLFTXHVWLRQQDLUHSURYLGHGE\
Eduix (Tampere, Finland).
4.4.2. POWER ANALYSIS
A power analysis was performed in prospective Study IV. We considered a 30% 
UHGXFWLRQLQSDLQLQWHQVLW\SULPDU\RXWFRPH156VLQWKH¿UVWSRVWRSHUDWLYHZHHN
DVDVLJQL¿FDQWFKDQJH8VLQJWKHUHVXOWVIURPDVWXG\RQSRVWWRQVLOOHFWRP\SDLQ
(Akural et al.), the average (median) estimated AUC value for NRSs during the 
¿UVWSRVWRSHUDWLYHZHHNIRUWKHFRQWUROJURXSZDV,45±115 To attain a 
SRZHURIDQGDVLJQL¿FDQFHOHYHORIĮHUURUZHFDOFXODWHGWKDWWR
GHPRQVWUDWHDUHGXFWLRQLQ156VGXULQJWKH¿UVWSRVWRSHUDWLYHZHHNZRXOG
require a patient population of 31 samples per group. We recruited 80 patients for 
each study group to compensate for potential dropouts and incomplete answers.
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5.1 CHARACTERISTICS OF PATIENTS IN STUDIES I, II, IV
7KHPDLQFKDUDFWHULVWLFVRI6WXGLHV,,,DQG,9DUHVXPPDUL]HGLQ7DEOH,Q
Study I on adult patients, 863 patients were operated on during the one-year study 
SHULRGRIZKLFKSDWLHQWVZHUHH[FOXGHGGXHWRFRPELQHGVXUJLFDOSURFHGXUH
The diagnosis was chronic tonsillitis in 76% of cases, and tonsillar hypertrophy with 
or without adenoid hypertrophy in 15% of cases. In Study II on pediatric patients, 
694 patients were operated on during the study period. Three tonsillectomies were 
performed in combination with neck cyst removal and were excluded. The diagnosis 
was tonsillar hypertrophy in 69% of cases and chronic tonsillitis in 14% of cases. In 
Study IV, 5 patients were excluded on the day of operation due to protocol violation 
and one patient due to anaphylactic reaction at the induction of anesthesia; 154 
patients (78 patients in the ropivacaine group and 76 in the control group) were 
LQFOXGHG7DEOH)LJXUH'XULQJWKH¿UVWZHHNSDWLHQWVSURYLGHG
complete results, including analgesics used according to instructions and the daily 
completion and return of questionnaires, and 101 patients (63%) during the second 
ZHHN7KHSURWRFROYLRODWLRQVDQGWKHGURSRXWVGXHWRDGYHUVHHɣHFWVHJ3219
or constipation) were associated with the rescue analgesic (codeine), not with the 
intervention.
Table 2. Patient characteristics. Categorical variables appear as a number and percentage; continuous 
variables appear as median and range. ASA, American Society of Anesthesiologists; TE, tonsillectomy; 
TEA, adenotonsillectomy.
Patient characteristics Study I  
(n=842)
Study II  
(n= 691)
Study IV  
intervention  
(n=78)
Study IV  
control  
(n=76)
Age, years,  
median (range)
32 (16–86) 7 (1–16) 25 (18–47) 27 (18–59)
Female/Male, n (%) 495 (59) / 347 (41) 338 (54) /353 (51) 35 (56) / 27 (44) 36 (63) /21 (37)
ASA I/II/III, % 73/23/4 86/13/3 80/20/0 77/33/0
TE/TEA, % 94/6 39/61 100 100
Duration of operation,  
minutes, median 
(range)
24 (4–165) 23 (3–88) 22 (9–40) 20 (7–50)

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5.2. RESULTS OF STUDIES I AND II
5.2.1. INCIDENCE OF POSTOPERATIVE COMPLICATIONS
Secondary PTH was the most common complication in both Studies I and II, 
occurring on postoperative days 5–8 (Figures 7a and 7b, respectively). In adults, the 
incidence of PTH was 14.5% (primary PTH 1.3%, secondary PTH 13%, reoperation 
1.5%), and 4.1% of patients experienced several episodes of PTH. In pediatric 
patients, the incidence of PTH was 7.1% (primary PTH 0.6%, secondary PTH 
UHRSHUDWLRQSDWLHQWVH[SHULHQFHGVHYHUDOHSLVRGHVRI37+DQG
5 patients (0.7%) required red blood cell transfusion due to secondary PTH. In 
pediatric patients, the overall incidence of unplanned contacts was 14% (revisits 
UHDGPLVVLRQSDLQIHYHUDQG3219
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Figure 7a. Study I, adults (n = 842). Number of patients with post-tonsillectomy hemorrhage according 
to bleeding category and postoperative day. Bleeding category: Grade I = stopped spontaneously or after 
clot removal, Grade II = required direct pressure or minor electrocautery under local anesthesia, Grade III 
= reoperation under general anesthesia. If a patient experienced several bleeding episodes, only the ﬁrst 
one was included.
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Figure 7b. Study II, pediatric patients (n = 691). Number of patients with post-tonsillectomy hemorrhage 
according to bleeding category and postoperative day. Bleeding category: Grade I = stopped spontaneously 
or after clot removal, Grade II = required direct pressure or minor electrocautery under local anesthesia, 
Grade III = reoperation under general anesthesia. If a patient experienced several bleeding episodes, only 
the ﬁrst one was included.
5.2.2. ASSOCIATION OF PERIOPERATIVE MEDICATION WITH COMPLICATIONS
NSAIDs, opioids, 5-HT receptor antagonists, or dexamethasone were not associated 
with an increased risk of complications in either the pediatric or adult population. In 
6WXG\,,ORFDODQHVWKHVLDSHULWRQVLOODULQ¿OWUDWLRQZLWKOLGRFDLQHZLWKHSLQHSKULQH
used for 130 patients (19%) was associated with an increased risk of secondary 
37+YVS25DVZHOODVWKHFRPELQDWLRQRIOLGRFDLQHZLWK
HSLQHSKULQHDQGELVPXWKVXEJDOODWHYVS25ZKLFKZDVXVHG
for 47 (7%) patients (Figure 8). Bismuth subgallate alone (9% of patients) was not 
associated with a risk of PTH.
To evaluate the impact of surgeons on the risk of PTH, they were divided into 
WZRFDWHJRULHVEDVHGRQWKHLULQGLYLGXDOULVNULVNRI37+VXUJHRQV*URXS
DQG!ULVNRI37+VXUJHRQV*URXS7KHXVHRIORFDODJHQWVZDVPRUH
FRPPRQLQ*URXSRISDWLHQWVWKDQLQ*URXSRISDWLHQWV:KHQQR
local agents were used, the risk of PTH was similar in both groups (Group 1: 3.6%, 
*URXS,Q*URXSSDWLHQWVWKDWUHFHLYHGOLGRFDLQHZLWKHSLQHSKULQHWKH
risk of PTH was higher than among those that had not received any local agents 
YVS ZKHUHDVLQ*URXSWKHGLɣHUHQFHZDVQRWVLJQL¿FDQW
YVS6LJQL¿FDQWO\DQLQFUHDVHGULVNZDVIRXQGLQ*URXS
again for the combination of lidocaine with epinephrine and bismuth subgallate 
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compared with those that did not receive any local anesthetic or hemostatic agents 
YVSRXWRIVXUJHRQVLQ*URXSWKHGLɣHUHQFHZDVQRW
VLJQL¿FDQWYVS RXWRIVXUJHRQV
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Figure 8. Cumulative proportion of post-tonsillectomy hemorrhage events among all patients (1–16 years 
of age) in relation to peritonsillar inﬁltration of lidocaine with epinephrine (yes) or without (no). Proportion 
appears as percentage (%).
5.3. RESULTS OF STUDY IV
5.3.1. PAIN INTENSITY ON THE DAY OF OPERATION AND NEED FOR RESCUE 
MEDICATION
7RSLFDOURSLYDFDLQHGLGQRWLQÀXHQFHSHDNSDLQLQWHQVLW\YDOXHVLQWKH3$&8156V
or NRSr) (median [IQR] 5 (3) ropivacaine, 5 (3) control, p = 0.54), or consumption 
of oxycodone in the PACU (median [IQR] 3 mg (4) ropivacaine, 3 mg (5) control, 
p = 0.56).
5.3.2. PAIN INTENSITY DURING THE FIRST AND SECOND WEEK AND 
CONSUMPTION OF ANALGESICS
The mean pain intensity on swallowing (NRSs) was moderate to severe on 
postoperative days 1–9 in the study group and on days 1–10 in the control group 
despite regular use of ibuprofen and the paracetamol-codeine combination (NRSs, 
156U7RSLFDOURSLYDFDLQHIDLOHGWRUHGXFH156VGXULQJWKH¿UVWSRVWRSHUDWLYHZHHN
S SULPDU\RXWFRPHDQGWKHGLɣHUHQFHGLGQRWUHDFKVLJQL¿FDQFHRQWKH
second week either (p = 0.05) (Figure 9a). Consumption of paracetamol-codeine 
WDEOHWVZDVVLJQL¿FDQWO\ORZHULQWKHVWXG\JURXSRQWKHVHFRQGSRVWRSHUDWLYHZHHN
(p = 0.006) (Figure 9b).
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Figure 9a. Pain intensity on swallowing (NRSs) during the 2-week follow-up (0–4 hours and 1–14 days 
postoperatively). Variables appear as mean and standard deviation. NRSs, numeric rating scale on swallowing.
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Figure 9b. Daily number of paracetamol-codeine tablets consumed during the 2-week follow-up (1–14 
days postoperatively). Variables appear as mean and standard deviation.
5.3.3. ADVERSE EVENTS
78% of patients in the ropivacaine group and 68% in the control group experienced 
IHHOLQJVRIQXPEQHVVLQWKHWKURDWLQWKH3$&8S 7KHUHZDVQRGLɣHUHQFH
LQWKHLQFLGHQFHRI3219HLWKHUURSLYDFDLQHJURXSFRQWUROJURXSS 
'DWDIURPWKHTXHVWLRQQDLUHVDWZHHNVRUPHGLFDOUHFRUGVDWRQHPRQWK
SRVWRSHUDWLYHO\ GLGQRW UHYHDO GLɣHUHQFHV LQ WKH ULVN RI RYHUDOO FRPSOLFDWLRQV
including the risk of PTH, although in sub-analysis Grade II PTH (hemostasis under 
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local anesthesia) in the study group was more common compared with the control 
group (18% vs. 8%, p = 0.048).
5.4. RESULTS OF STUDY III
5.4.1. CHARACTERISTICS OF INCLUDED STUDIES
7KHV\VWHPDWLFUHYLHZLQFOXGHGUDQGRPL]HGGRXEOHEOLQGSODFHERFRQWUROOHG
studies representing 1816 patients, of which 9 could be combined in a pooled 
meta-analysis. Two studies compared paracetamol, 9 NSAIDs, 10 dexamethasone, 
JDEDSHQWLQSUHJDEDOLQGH[WURPHWKRUSKDQNHWDPLQHDQGR[\FRGRQH
7KHUHZHUHVLQJOHGRVHDQGPXOWLSOHGRVHVWXGLHV7KHGXUDWLRQRIIROORZXS
UDQJHGIURPPLQXWHVWRGD\VLQPRVWVWXGLHVLWZDVKRXUVRUOHVV3DLQ
LQWHQVLW\ZDVWKHSULPDU\RXWFRPHLQVWXGLHVUHVFXHDQDOJHVLDLQDQGVWXGLHV
GLGQRWVSHFLI\WKHSULPDU\RXWFRPHSUHVHQWLQJDULVNRIELDV7KHPDLQ¿QGLQJ
was the scarcity of data and short duration of studies that investigated analgesics 
for post-tonsillectomy pain, which is clinically relevant considering the number of 
tonsillectomies performed yearly and the intensity of pain following the procedure 
(Table 3).
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Table 3. Reported pain intensity values during follow-up time. pod; post-operative day, NSAIDs; non-
inﬂammatory agents, * = pain intensity values not available;  
Ÿ = pain relief; Ŷ= VAS/VRS/NRS, ż = VASs/VRSs/NRSs; Ɣ = VASr/VRSr/NRSr and VASs/VRSs/NRSs.
Studies 1h 2h 4h 12
h
24
h
2p
od
3p
od
4p
od
5p
od
6p
od
7p
od
8p
od
9p
od
10
po
d
Paracetamol
Atef 2008 Ɣ Ɣ Ɣ Ɣ
Salonen 2009 Ɣ Ɣ Ɣ
NSAIDs 
Parker 1986, ibuprofen, acetylsalicylic acid Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ Ÿ
Rorarius 1993, indometacin, diclofenac * *
Tarkkila 1999, ketoprofen Ɣ Ɣ
Salonen 2001, ketoprofen Ɣ Ɣ Ɣ Ɣ
Naesh 2005, rofecoxib Ŷ Ŷ Ŷ
Ismail 2010, lornoxicam Ɣ Ɣ Ɣ Ɣ Ɣ
Mowaﬁ 2011, lornoxicam Ɣ Ɣ Ɣ Ɣ Ɣ
Xie 2012, parecoxib Ɣ Ɣ Ɣ Ɣ Ɣ
Ng 2017, celecoxib Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ
Dexamethasone
Fields 1994 Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ
Carr 1999 ż ż ż ż ż ż ż ż ż ż
Stewart 2002 ż ż ż ż ż ż ż ż ż ż
Al-Shehri 2004 Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ
Rujirojindakul 2008 Ŷ Ŷ Ŷ Ŷ
Lachance 2008 ż ż ż ż ż ż ż
Vaiman 2011 ż
Vaiman 2011 ż
Thimmasettaiah 2012 Ŷ Ŷ
Khafagy 2013 Ŷ Ŷ Ŷ Ŷ Ŷ Ŷ
Gabapentinoids 
Mikkelsen 2006, gabapentin Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ
Jeon 2009, gabapentin Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ
Abdelmageed 2010, gabapentin Ŷ Ŷ Ŷ
Mathiesen 2011, pregabalin Ɣ Ɣ Ɣ
NMDA-antagonists
Kawamata 1998, dextrometorphan Ɣ Ɣ Ɣ Ɣ Ɣ Ɣ
Raﬁei 2012, dextrometorphan Ɣ
Van Elstraete 2004, ketamine Ɣ Ɣ Ɣ Ɣ Ɣ
Opioids
Vaiman 2012, oxycodone ż
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5.4.2. POST-TONSILLECTOMY PAIN AND ANALGESIA
7KHPHDQSDLQ LQWHQVLWLHVZHUHPRGHUDWH WRVHYHUHDIWHU WRQVLOOHFWRP\IRU±
weeks among adult patients in both the placebo and treatment groups (Figures 
10a and 10b).
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Figure 10a. Pain intensity in placebo groups on postoperative days 1–10. NRSs, numeric rating scale on 
swallowing; VAS, visual analog scale; VRS, visual rating scale.
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ŵĞĚŝĂŶ
&ŝĞůĚƐ͕ϭϵϵϰ͕s^
ŵĞĂŶ
Ăƌƌ͕ϭϵϵϵ͕s^Ɛ
ŵĞĂŶ
^ƚĞǁĂƌƚ͕ϮϬϬϮ͕
s^ƐŵĞĂŶ
ůͲ^ŚĞŚƌŝ͕s^
ŵĞĂŶ
ZƵũŝƌŽũŝŶĚĂŬƵů
ϮϬϬϴ͕sZ^ŵĞĂŶ
>ĂĐŚĂŶĐĞϮϬϬϴ͕
s^ƐŵĞĂŶ
<ŚĂĨĂŐǇϮϬϭϯ͕
ŐǇƉƚŝs^ŵĞĂŶ
:ĞŽŶϮϬϬϵ͕s^Ɛ
ŵĞĂŶ
<ĂǁĂŵĂƚĂ͕ϭϵϵϴ͕
s^ƐŵĞĂŶ
Figure 10b. Pain intensity (pain intensity or pain in swallowing) in the treatment groups on postoperative 
days 1–10. NRSs, numeric rating scale on swallowing; VAS, visual analog scale; VRS, visual rating scale.
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3DUDFHWDPROVLQJOHGRVHRIJLYLQWUDRSHUDWLYHO\DQGPXOWLSOHGRVHVXSWRJLY
RQWKHGD\RIRSHUDWLRQVKRZHGDVLJQL¿FDQWGHFUHDVHLQSDLQLQWHQVLW\YLVXDODQDORJ
VFDOHRQVZDOORZLQJDWKRXUVHTXLYDOHQWWRDQUHGXFWLRQ>íS@
EXWQRPRUHDWKRXUVDQGGHFUHDVHGWKHQHHGIRURSLRLGVZLWKLQKRXUV116,117 
All NSAIDs (ketoprofen, ibuprofen, acetylsalicylic acid, diclofenac, indomethacin, 
lornoxicam, parecoxib, rofecoxib) reduced pain intensity or the need for opioids 
RUERWKZLWKLQKRXUVRQHVWXG\RQFHOHFR[LE IRUSRVWRSHUDWLYHGD\VGLG
QRWKDYHDQ\DQDOJHVLFHɣHFW In all studies, the majority of patients needed 
rescue analgesics, indicating that NSAIDs alone do not provide adequate analgesia 
for tonsillectomy patients. Meta-analysis was possible only for two studies on 
NHWRSURIHQZKLFKIDLOHGWRGHFUHDVHSDLQLQWHQVLW\DWKRXUVDQGDWKRXUVS
 S UHVSHFWLYHO\KRZHYHUWKHQHHGIRUUHVFXHDQDOJHVLFVZLWKLQ
hours was reduced (Figure 11).116,117 Dexamethasone reduced pain intensity or the 
need for rescue analgesics in all 10 studies. In the pooled analysis, a single 
LQWUDRSHUDWLYHGRVHRIGH[DPHWKDVRQHGHFUHDVHGSDLQLQWHQVLW\HTXLYDOHQWWRDW
KRXUVíSEXWQRORQJHUDWKRXUVS )LJXUH5HGXFWLRQ
RISDLQ LQWHQVLW\ ODVWHGEH\RQGWKH¿UVWSRVWRSHUDWLYHGD\ LQDOO WKUHHPXOWLSOH
dose studies and in one single-dose study. In the pooled analysis, gabapentinoids 
GHFUHDVHGSDLQLQWHQVLW\HTXLYDOHQWWRDWKRXUVíSDQG
DWKRXUVíS)LJXUH137-139 
*DEDSHQWLQ±PJSRRQWKHGD\RIRSHUDWLRQUHGXFHGWKHQHHGIRU
UHVFXHDQDOJHVLFVZLWKLQKRXUVDQGSUHRSHUDWLYHSUHJDEDOLQPJZLWKLQ
hours. Dextromethorphan 45 mg p.o. preoperatively reduced pain intensity within 
KRXUVDQGWKHWRWDOGRVHRIUHVFXHDQDOJHVLFVZLWKLQKRXUVLQERWKLQFOXGHG
studies and in the other study for 6 postoperative days. Ketamine 0.5 mg kgí i.v. 
EROXVZLWKǋJNJí miní i.v. infusion intraoperatively failed to show an analgesic 
HɣHFW143 
2[\FRGRQHPJKíPJLYLQIXVLRQGXULQJ±KRXUVSRVWRSHUDWLYHO\
GHFUHDVHGSDLQLQWHQVLW\DWKRXUVDVH[SHFWHG144 In summary, when any of the 
DQDOJHVLFVRUGH[DPHWKDVRQHZHUHXVHGDORQHWKHDQDOJHVLFHɣHFWGLGQRWUHDFK
clinical meaningfulness due to the high pain intensity.
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5. Results
Figure 11. Forest plot showing the effect of perioperatively administered analgesics and dexamethasone on 
pain intensity at 24 hours. Pain intensity values (scale 0–10) with conﬁdence intervals (CIs). Data evaluated 
using a random effects model. NMDA, N-methyl-D-aspartate; NSAID, nonsteroidal anti-inﬂammatory drug; 
SD, standard deviation.
5.4.3. ADVERSE EVENTS
The incidence of PTH was reported in the paracetamol, NSAID, and dexamethasone 
studies, in which the risk of PTH was not increased. Dexamethasone reduced PONV 
GXULQJ±KRXUVSRVWRSHUDWLYHO\ULVNUDWLR55SUHÀHFWLQJ
DQDQWLHPHWLFDQGPD\EHDOVRRSLRLGVSDULQJHɣHFW*DEDSHQWLQRLGVGHFUHDVHG
postoperative vomiting also (RR 0.55, p = 0.03); however, in one study with high 
and multiple doses of gabapentin, adverse events were common. Dextromethorphan 
or ketamine studies did not report an increased risk of adverse events. Serious 
adverse events were reported in none of the included studies.
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6. DISCUSSION
6.1. INCIDENCE OF COMPLICATIONS
In the retrospective Study II in pediatric patients, 14% of patients contacted hospital, 
10% visited physician and 8% were admitted to the ward, 7.1% due to PTH, 3% due 
to pain; these results are in line with literature, somewhat less than in the previous 
prospective study in our clinic (17%).  
In Study II, the incidence of primary PTH was 0.6% and secondary PTH 6.5%, 
DQGUHRSHUDWLRQXQGHUJHQHUDODQHVWKHVLD*UDGH,,,37+ZDVUHTXLUHGIRURI
patients (needed for smaller children which increases the incidence of reoperation 
rate). In Study I in adults, the incidence of PTH was 14.5% (primary PTH 1.3%, 
VHFRQGDU\37+UHRSHUDWLRQ,QWKHSURVSHFWLYH6WXG\,9WKHRYHUDOO
LQFLGHQFHRI37+ZDV,QWKHURSLYDFDLQHJURXSWKHULVNRI*UDGH,,37+ZDV
VLJQL¿FDQWO\KLJKHU²YVS &,RIGLɣHUHQFH±EXWZKHQ
compared with Study I, the incidence of PTH (14.5%) was within the same range; and 
PD\GXHWRFKDQFHDQGWKHGLɣHUHQFHZDVEDUHO\VLJQL¿FDQWZLWKZLGHFRQ¿GHQFH
LQWHUYDOKRZHYHUWKHHɣHFWRIURSLYDFDLQHRQWKHULVNRI37+FDQQRWEHH[FOXGHG
Questionnaires revealed that in both groups almost 50% of the patients reported 
EORRGLQVDOLYDDQGPRUHWKDQUHSRUWHGFOHDUEORRGIURPWKHVXUJLFDOVLWH
which describes the situation at home and highlights the fact that the incidence of 
PTH is much more common than previously thought. Patients are given instruction 
that bleeding usually ceases by itself in few minutes and to contact the unit that 
WUHDWHGWKHSDWLHQWRUDQHPHUJHQF\XQLWDIWHURɤFHKRXUVLIWKHSRVVLEOHEOHHGLQJRI
the throat does not cease within 10-15 minutes. Some patients tolerate the recovery 
process better, whereas others contact the hospital more easily. 
Patient education is of utmost importance, as the surgery carries risk of very 
rare but serious complications. Most patients are operated as outpatients, leaving 
the hospital on the day of operation, on the condition that they have company 
overnight and stay within one hour’s reach of hospital in case they need to come 
back. Outpatient tonsillectomy has been proven to be safe, and it is more convenient 
for patients and caregivers; however, patient selection is important.
6.2. RISK OF POST-TONSILLECTOMY HEMORRHAGE
7KHVWXGLHVFRQ¿UPHGWKHSUHYLRXVO\UHSRUWHGSUHGLVSRVLWLRQVWR37+²ROGHUDJH
and male gender—after tonsillectomy. In our studies, the incidence of PTH was 
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higher among adult patients (14.5%) than in pediatric patients (7.1%). Indication 
for surgery was not an independent risk factor for PTH.
3HULWRQVLOODU LQ¿OWUDWLRQRI OLGRFDLQHZLWK HSLQHSKULQHZDV FRPPRQO\XVHG
among pediatric patients and was found to increase the risk of secondary PTH. 
Increased risk of PTH was associated with the use of systemic hemostatic or local 
hemostatic and anesthetic agents in both Studies I and II, but these agents are not 
used commonly in adult patients, so the numbers were small and separate statistical 
DQDO\VHVZHUHQRWSRVVLEOHLQ6WXG\,,Q6WXG\,,ORFDOSHULWRQVLOODULQ¿OWUDWLRQRI
lidocaine with epinephrine was used for 130 pediatric patients (19%) and it was 
DVVRFLDWHGZLWKLQFUHDVHGULVNRIVHFRQGDU\37+YVS25
Also, a combination of lidocaine with epinephrine and topical bismuth subgallate 
XVHGIRURISDWLHQWVLQFUHDVHGWKHULVNRI37+YVS25
Bismuth subgallate alone was not associated with a risk of PTH. To evaluate the 
impact of surgeons on the risk of PTH, they were divided into two categories based 
RQWKHLULQGLYLGXDOULVNULVNRI37+VXUJHRQV*URXSDQG!ULVN
RI37+VXUJHRQV*URXS7KHXVHRIORFDODJHQWVZDVPRUHFRPPRQLQ*URXS
RISDWLHQWVWKDQLQ*URXSRISDWLHQWV:KHQQRORFDODJHQWVZHUH
XVHGWKHULVNRI37+ZDVVLPLODULQERWKJURXSV*URXS*URXS
Whether the association is due to lidocaine with epinephrine, the skills of surgeons, 
or both cannot be convincingly concluded from this retrospective study material.
,QWKHOLWHUDWXUHSHULWRQVLOODULQ¿OWUDWLRQRIOLGRFDLQHZLWKHSLQHSKULQHKDVEHHQ
suspected to increase the risk of PTH due to masking of inadequate hemostasis, 
EXWWKHHɣHFWLVH[SHFWHGWRDSSHDULPPHGLDWHO\DVWKHYDVRFRQVWULFWLYHHɣHFWRI
HSLQHSKULQHZHDUVRɣ145 On the other hand, from a surgical point of view, without 
local anesthesia associated vasoconstriction, good visibility is achieved of the veins 
and every bleeding vessel will be coagulated during surgery. The better hemostasis 
DQGZRXQGKHDOLQJFRXOGDSSHDUODWHUDWWKHHQGRIWKH¿UVWSRVWRSHUDWLYHZHHN
during the peak incidence of PTH. The increased risk of postoperative hemorrhage 
GXHWRWKHHɣHFWRIORFDODQHVWKHVLDKDVQRWEHHQUHSRUWHGEHIRUHWRRXUNQRZOHGJH
,QWRQVLOOHFWRP\VWXGLHVRQORFDODQHVWKHWLFVWKHIROORZXSWLPHVDUHW\SLFDOO\
hours or less and therefore secondary PTH cannot be detected. Local anesthetics 
LQKLELWZRXQGKHDOLQJE\WKHLUDQWLSUROLIHUDWLYHHɣHFWRQPDQ\FHOOW\SHVLQFOXGLQJ
mesenchymal stem cells essential in wound healing in a dose-dependent manner 
(in vitro and animal models); however, the clinical meaningfulness of this is not yet 
clear.146 Also, epinephrine has been shown to decrease cell migration and potentiate 
SHUVLVWHQWLQÀDPPDWLRQLQLQIHFWHGZRXQGV147 An open wound in the oral cavity 
LVYXOQHUDEOHDQGHYHQPLQRUDGYHUVHHɣHFWVRIPHGLFDWLRQVVXFKDV LPSDLULQJ
wound healing may increase the risk of PTH. In our clinic, the use of local lidocaine 
with epinephrine in tonsillectomies has decreased over the years; however, it is 
used often in tonsillotomies, which are now more common than tonsillectomies in 
pediatric patients. Whether lidocaine with epinephrine increases the risk of PTH 
in tonsillotomies remains to be studied.
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NSAIDs and dexamethasone were used for the majority of patients in large 
retrospective Studies I and II, and fortunately the risk of PTH or other complications 
was not increased. The evidence regarding the association of PTH with NSAIDs, 
and to a lesser extent also dexamethasone, is controversial probably due to 
many confounding factors. In our institution, the operation technique is quite 
homogenous, and the sample size was large, and thus the result is reassuring for 
the safe use of both NSAIDs and dexamethasone at least in our institution with the 
present perioperative treatment protocol. The systematic review (Study III) did not 
reveal an increased risk of PTH either. Guidelines recommend the use of NSAIDs 
and dexamethasone for the prevention of pain and PONV, and the evidence from 
our studies supports this conclusion.
6.3. POST-TONSILLECTOMY PAIN
Only a very few studies on tonsillectomy (pain or PTH) have been published that 
have a follow-up of more than few days. A study on adults (1995) with a follow-up of 
10 days reported moderate to severe pain intensity lasting for 6 postoperative days.53 
,QWKHVWXG\RI6DUQ\RISDWLHQWVH[SHULHQFHGVHYHUHSDLQXQWLOWKHWK
postoperative day, then declining (pain type II, Figure 1).54 In Study III (systematic 
review) and IV (ropivacaine study) the mean pain intensities were moderate to 
VHYHUHDIWHUWRQVLOOHFWRP\IRU±ZHHNVDQGWKHQGHFOLQLQJFRQ¿UPLQJUHVXOWV
from few previous studies.
6.4. ANALGESIA
6\VWHPDWLF UHYLHZ UHYHOHG WKDW WKH HYLGHQFHRQHɤFDF\RI DQDOJHVLFV IRUSRVW
tonsillectomy pain is minimal due to lack of good/high quality studies. Follow-up 
SHULRGVVKRXOGEHORQJHUZHHNVDQGSDLQVKRXOGEHPHDVXUHGVHSDUDWHO\DW
rest and on swallowing and preferably by global pain measurements, such as brief 
pain inventory (BPI). 
6WXG\,,,FRQ¿UPHGDZHDNWRPRGHUDWHDQDOJHVLFHɣHFWRISDUDFHWDPRO16$,'V
dexamethasone, gabapentinoids, and dextromethorphan for post-tonsillectomy 
pain on the day of operation and dexamethasone in multiple doses beyond the 
¿UVWSRVWRSHUDWLYHGD\,QWKHRQHLQFOXGHGVWXG\RQDGXOWSDWLHQWVNHWDPLQHLY
bolus of 0.5 mg kg-1 after induction and infusion of 0.1 mg kg-1 h-1 until end of the 
VXUJHU\GLGQRWUHGXFHSDLQLQWHQVLW\RUQHHGIRURSLRLGVVLJQL¿FDQWO\GXULQJKRXUV
of follow-up.143$GLɣHUHQFHPD\KDYHEHHQREVHUYHGZLWKODUJHUSDWLHQWPDWHULDO
and longer follow up, given that ketamine has been shown to reduce postoperative 
pain in pediatric tonsillectomy patients.97 Systematic review and meta-analysis in 
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SHGLDWULFWRQVLOOHFWRP\SDWLHQWVUHSRUWHGUHGXFHGSDLQLQWHQVLWLHVZLWKLQ¿UVW
KRXUVDQGQHHGIRUDQDOJHVLFVZLWKLQKRXUVSRVWRSHUDWLYHO\LQNHWDPLQHJURXSV
compared with control groups.95,QWKHVXEJURXSDQDO\VLVSHULWRQVLOODULQ¿OWUDWLRQ
RINHWDPLQHZDVPRUHHɣHFWLYHWKDQLQWUDYHQRXVNHWDPLQHLQUHGXFLQJSRVWRSHUDWLYH
SDLQZLWKLQKRXUVRIIROORZXSLPPHGLDWHO\DIWHUVXUJHU\LQNHWDPLQHJURXSV
compared to -0.8 in control groups, measured with pain intensity scale 0-10). Locally 
DGPLQLVWHUHGNHWDPLQHZDVVXVSHFWHGWREHPRUHHɤFLHQWGXHWRLWVGLUHFWHɣHFWRQ
WKHSHULSKHUDOQHUYHHQGLQJVDQGORQJHUODVWLQJSKDUPDFRNLQHWLFHɣHFW97,149 
On the day of operation, pain is not yet severe, and is easily controlled at the 
hospital. On following days as pain intensity is moderate to strong, and it was obvious 
from studies III and IV that treatment with any analgesics or dexamethasone alone 
LVQRWHɣHFWLYHHQRXJKWRUHDFKFOLQLFDOO\PHDQLQJIXOUHGXFWLRQSDLQLQWHQVLW\OHVV
than 3/10). 
In Study IV, ropivacaine did not reduce the peak pain intensity values or 
FRQVXPSWLRQRIUHVFXHPHGLFDWLRQGXULQJWKHK3$&8IROORZXSZKLFK LVDQ
LQGLFDWLRQRILQVXɤFLHQWHQWU\RIGUXJWRWKHHɣHFWVLWH([SODQDWLRQFRXOGEHIDVW
clearance from the tissue, or that only small part of ropivacaine was in its non-ionized 
lipid soluble form (because of the acidic environment under the wound) and was 
WKHUHIRUHXQDEOHWRSDVVQHUYHPHPEUDQHVXɤFLHQWO\ Although ropivacaine failed 
WRUHGXFHSDLQLQWHQVLW\GXULQJWKHZHHNIROORZXSFRQVXPSWLRQRISDUDFHWDPRO
FRGHLQHWDEOHWVZDVVLJQL¿FDQWO\UHGXFHGRQWKHVHFRQGZHHNS 7KLVZDV
a secondary outcome; however, the large patient sample increases the probability, 
that the ability of topical ropivacaine to decrease pain intensity during the second 
SRVWRSHUDWLYHZHHNLVDWUXHDQDOJHVLFHɣHFW7KHUHDVRQZK\URSLYDFDLQHVHHPHGWR
modify pain as late as on the second postoperative week could be partial prevention 
RIK\SHUDOJHVLDWKDWGHFOLQHGVRRQHULQWKHWUHDWPHQWJURXS$VLPLODU¿QGLQJZDV
reported in a tonsillectomy study comparing hot and cold technique in which the 
other side (tonsil) was operated with cold instruments and the other with a hot 
technique: pharyngeal pain intensity and otalgia were lower on the hot technique 
side compared to cold technique side on the day of operation, but higher on the 
second postoperative week.115 Authors suspected that slower healing on the side of 
hot technique resulted in more intense nociceptive stimuli on exposed nerve endings 
causing central sensitization, hyperalgesia and prolonged pain, and therefore the 
GLɣHUHQFHEHWZHHQVLGHVDSSHDUHGODWHUGXULQJWKHVHFRQGSRVWRSHUDWLYHZHHN
7KHHɤFDF\RIWRSLFDOURSLYDFDLQHIRUWKHSUHYHQWLRQRISRVWWRQVLOOHFWRP\SDLQKDV
been reported previously in pediatric patients and in mixed populations.Surgery 
requires less invasive technique and need for coagulation in pediatric patients 
operated mainly for tonsillar hypertrophy, and thus the operation site (tonsillar 
bed) may be more permeable than in adults operated mainly for chronic tonsillitis, 
DOORZLQJWRSLFDODQHVWKHWLFVWRSDVVWRWKHHɣHFWVLWHPRUHHDVLO\ 
55
7. LIMITATIONS
The weakness of Studies I and II is that because several simultaneous factors play 
a role in the pathogenesis of PTH that are not possible to detect in retrospective 
studies, causal conclusions cannot be made. Additionally, only limited insight is 
possible to problems rising at home after surgery. 
Optimally, a systematic review and meta-analysis combines data from many 
high-quality studies resulting in a large patient population, giving the possibility 
WRHVWLPDWHWUHDWPHQWHɣHFWVPRUHSUHFLVHO\WKDQLVSRVVLEOHLQVLQJOHVWXGLHV,Q
Study III, a thorough search was performed by using multiple databases and by 
hand searching reference lists of included trials, and therefore all relevant studies 
are likely to be included during the study period. Only good to high quality studies 
(Oxford Quality Scoring Scale was used for assessing quality) were included for 
the analysis and the overall risk of bias, measured by the Cochrane tool of bias, 
was low.111+RZHYHUVWXGLHVGLGQRWUHSRUWWKHSULPDU\RXWFRPHDQGLWLV
unclear how sample size was calculated, and how reliable obtained results within 
studies are. The overall risk of bias can be assumed higher, than shown by the 
Cochrane risk of bias tool, which maybe does not weigh the missing of the primary 
outcome in the calculation as much as it should. Combining results in a pooled 
meta-analysis was possible only in selected studies due to limited and heterogenic 
data. The meta-analysis was nevertheless conducted, with the description of this 
limitation, to allow rough comparison between studies and study groups. Due to 
these limitations, results of the systematic review must be interpreted with caution. 
In Study IV, the use of paracetamol-codeine combination analgesics up to 8 times 
GDLO\DWKRPHPD\KDYHPDVNHGWKHHɣHFWRIWRSLFDOURSLYDFDLQHVRWKDWGLɣHUHQFHV
LQSDLQLQWHQVLWLHVGLGQRWEHFRPHVLJQL¿FDQW'XHWRLQWHQVLYHSRVWWRQVLOOHFWRP\
pain, the standard use of analgesics was nevertheless considered only possible option 
IRUHWKLFDOUHDVRQV7KHRWKHULVVXHWKDWPD\KDYHDɣHFWHGWKHRXWFRPHZDVWKDW
ropivacaine was applied in the squeezed swabs, so the dose was not exact and 
PD\EHZDVQRWKLJKHQRXJK7LPHRI¿YHPLQXWHVDOORZHGIRUDEVRUSWLRQKDGEHHQ
used in similar studies, but it may have been too short; it was chosen for practical 
reasons, so that the application time would be within acceptable limits in everyday 
clinical practice.  
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8. FUTURE ASPECTS
Multimodal analgesia for tonsillectomy needs further developing. Antihyperalgesic 
adjuvants such as ketamine as intravenous infusion or locally for the prevention of 
post-tonsillectomy pain should be studied in adults. For safety reasons, it would 
be important to investigate whether lidocaine with epinephrine increases the risk 
of PTH in tonsillotomies.  Well-conducted studies in post-tonsillectomy pain with 
IROORZXSRIZHHNVDUHQHHGHGIRULPSURYHPHQWRIFDUHDQGSDWLHQWVDWLVIDFWLRQ
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9. CONCLUSIONS 
 'XULQJWKHVWXG\SHULRGRIPRQWKVLQRXULQVWLWXWLRQ37+ZDVWKHPRVW
common complication, in adults 14.5% (primary PTH 1.3%, secondary 
37+UHRSHUDWLRQDQGLQSHGLDWULFSDWLHQWVSULPDU\37+
 VHFRQGDU\ 37+  UHRSHUDWLRQ  ,Q SHGLDWULF SDWLHQWV WKH
overall incidence of unplanned postoperative contact was 14%, (revisits 10%, 
UHDGPLVVLRQSDLQIHYHU3219
 3DUDFHWDPRO16$,'VGH[DPHWKDVRQHR[\FRGRQHRU+7DQWDJRQLVWVZHUH
not associated with an increased risk of postoperative complications. The use of 
ORFDODQHVWKHVLDZLWKSHULWRQVLOODULQ¿OWUDWLRQRIOLGRFDLQHZLWKHSLQHSKULQHZDV
associated with an increased risk of secondary PTH among pediatric patients.
3. Tonsillectomy is a painful procedure. The mean pain intensity was moderate 
WRVHYHUHIRU±ZHHNVSRVWRSHUDWLYHO\ LQDGXOWSDWLHQWVGHVSLWHDQDOJHVLF
treatment.
 6\VWHPDWLFUHYLHZUHYHOHGWKDWWKHHYLGHQFHRQHɤFDF\RIDQDOJHVLFVIRUSRVW
tonsillectomy pain is minimal due to lack of good quality studies. Paracetamol, 
NSAIDs, dexamethasone, gabapentinoids, and dextromethorphan had a 
ZHDNWRPRGHUDWHDQDOJHVLFHɣHFWRQSRVWWRQVLOOHFWRP\SDLQRQWKHGD\RI
RSHUDWLRQ'H[DPHWKDVRQHLQPXOWLSOHGRVHVKDGDQDOJHVLFHɤFDF\EH\RQG
one postoperative day; however, risks should be considered if treatment is 
prolonged. None of the studied analgesics or dexamethasone alone were 
HɣHFWLYHHQRXJKWRSURYLGHFOLQLFDOO\PHDQLQJIXODQDOJHVLDSDLQLQWHQVLW\OHVV
than 3/10) for treatment of post-tonsillectomy pain, and therefore multimodal 
DQDOJHVLDLVQHHGHGLQRUGHUWRRɣHUSDWLHQWVDGHTXDWHSDLQFRQWURO
5. Topical ropivacaine applied to the tonsillar bed after removal of the tonsils 
IDLOHGWRUHGXFHSRVWWRQVLOOHFWRP\SDLQGXULQJWKH¿UVWSRVWRSHUDWLYHZHHN
but seemed to modify pain during the second postoperative week. 
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VXFKDVQXPEQHVVRIWKHWKURDWGXULQJWKHSDVW
KRXUV"1R$OLWWOH,DPDEOHWRVZDOORZVROLGIRRG&RQVLGHUDEOHWURXEOH,DPRQO\DEOHWRVZDOORZOLTXLGV
+DYH\RXKDGWKHVHQVDWLRQRIDIRUHLJQREMHFWLQ\RXUWKURDWGXULQJWKHSDVWKRXUV"1R$OLWWOH$JUHDW
GHDO
+DYH\RXIHOWOLTXLGWULFNOLQJLQWR\RXUQRVHRUZLQGSLSHZKLOHVZDOORZLQJ³JRLQJGRZQWKHZURQJSLSH´
GXULQJWKHSDVWKRXUV"1R$OLWWOH$JUHDWGHDO
+DYH\RXH[SHULHQFHGEOHHGLQJLQWKHDUHDDIIHFWHGE\WKHVXUJHU\GXULQJWKHSDVWKRXUV"1R$OLWWOH
EORRGPL[HGZLWKVDOLYD<HVFOHDUEORRG
')HHGEDFN
:KDWZRXOG\RXOLNHWRWHOOWKHPHGLFDOVWDIIRUUHVHDUFKJURXS"
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APPENDIX 2
WK^dKWZd/sW/ED/d/KE&KZh>ddKE^/>>dKDzKhdWd/Ed
ZĞĐŽŵŵĞŶĚĂƚŝŽŶĨŽƌƉŚǇƐŝĐŝĂŶĂƚƚŚĞ,ĞůƐŝŶŬŝhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂů͕ĞƉĂƌƚŵĞŶƚŽĨKƚŽƌŚŝŶŽůĂƌǇŶŐŽůŽŐǇͶ,ĞĂĚ
ĂŶĚEĞĐŬ^ƵƌŐĞƌǇ
DĞĚŝĐĂƚŝŽŶǁŚĞŶƚŚĞƉĂƚŝĞŶƚĚŽĞƐŶŽƚŚĂǀĞĐŽŶƚƌĂŝŶĚŝĐĂƚŝŽŶƐ͗
Ͳ /ďƵƉƌŽĨĞŶ ϲϬϬʹϴϬϬŵŐ ϯ ƚŝŵĞƐ ĚĂŝůǇ͕ ƌĞŐƵůĂƌůǇ ĨŽƌ ŽŶĞ ǁĞĞŬ͕ ƚŚĞŶ ĂƐ ŶĞĞĚĞĚ͘ E с ϭϬϬ͘ ůƚĞƌŶĂƚŝǀĞůǇ͕ ĂŶŽƚŚĞƌ
ŶŽŶƐƚĞƌŽŝĚĂůĂŶƚŝͲŝŶĨůĂŵŵĂƚŽƌǇĚƌƵŐ;E^/Ϳ
Ͳ WĂƌĂĐĞƚĂŵŽůϱϬϬŵŐнĐŽĚĞŝŶĞϯϬŵŐ ;WĂŶĂĐŽĚΠͿϭʹϮ ƚĂďůĞƚƐϮʹϰ ƚŝŵĞƐĚĂŝůǇ͕ ƌĞŐƵůĂƌůǇ ĨŽƌŽŶĞǁĞĞŬ͕ ƚŚĞŶĂƐ
ŶĞĞĚĞĚ͘EсϲϬͲϭϬϬ͘dŚĞƉƌĞƐĐƌŝƉƚŝŽŶŵƵƐƚďĞǁƌŝƚƚĞŶǁŝƚŚĂƐƚĂƚĞŵĞŶƚƚŚĂƚŝƚŵĂǇŶŽƚďĞƌĞŶĞǁĞĚ͘
Ͳ ^ŽĚŝƵŵƉŝĐŽƐƵůĨĂƚĞ;>ĂǆŽďĞƌŽŶΠͿϮ͘ϱŵŐĐĂƉƐƵůĞƉƌĞƐĐƌŝƉƚŝŽŶ͘ŽƐĂŐĞϮʹϰĐĂƉƐƵůĞƐŝŶƚŚĞĞǀĞŶŝŶŐĂƐŶĞĞĚĞĚ͘Eс
ϱϬ͘
ůƚĞƌŶĂƚŝǀĞŵĞĚŝĐĂƚŝŽŶǁŚĞŶĐŽŶƚƌĂŝŶĚŝĐĂƚŝŽŶƐƚŽE^/Ɛ͗
Ͳ WĂƌĂĐĞƚĂŵŽůϭŐƉĞƌŽƌĂůůǇϯʹϰƚŝŵĞƐĚĂŝůǇ͕ƌĞŐƵůĂƌůǇĨŽƌŽŶĞǁĞĞŬ͕ƚŚĞŶĂƐŶĞĞĚĞĚ͘EсϭϬϬ͘
Ͳ dƌĂŵĂĚŽůϱϬʹϭϬϬŵŐƉĞƌŽƌĂůůǇϭʹϯƚŝŵĞƐĚĂŝůǇ͕ƌĞŐƵůĂƌůǇĨŽƌŽŶĞǁĞĞŬ͕ƚŚĞŶĂƐŶĞĞĚĞĚ͘EсϭϬϬ͘
/ĨƚŚĞĂďŽǀĞŵĞĚŝĐĂƚŝŽŶŝƐŝŶĂĚĞƋƵĂƚĞĂŶĚƚŚĞƉĂƚŝĞŶƚĐŽŵĞƐƚŽƚŚĞŚŽƐƉŝƚĂůďĞĐĂƵƐĞŽĨŝŶƚŽůĞƌĂďůĞƉĂŝŶ͕ĐŽŶƐŝĚĞƌƌĞƉůĂĐŝŶŐ
ƉĂƌĂĐĞƚĂŵŽůнĐŽĚĞŝŶĞŽƌƚƌĂŵĂĚŽůǁŝƚŚůŽŶŐͲĂĐƚŝŶŐŽǆǇĐŽĚŽŶĞнŶĂůŽǆŽŶĞ;dĂƌŐŝŶŝƋͿΠϭϬͬϱŵŐϭƚĂďůĞƚƉĞƌŽƌĂůůǇƚǁŽƚŝŵĞƐ
ĚĂŝůǇ͕Eсϭϰ͘
dŚĞĨŝƌƐƚĚŽƐĞŝƐĂĚŵŝŶŝƐƚĞƌĞĚĂƚƚŚĞŚŽƐƉŝƚĂůĂŶĚƉĂƚŝĞŶƚŝƐŵŽŶŝƚŽƌĞĚϯͲϰŚŽƵƌƐƉƌŝŽƌƚŽĚŝƐĐŚĂƌŐĞ͘dŚĞƉĂƚŝĞŶƚŵƵƐƚďĞŽĨ
ŶŽƌŵĂů ƐŝǌĞ ;х ϱϬŬŐͿ͕ǁŝƚŚŽƵƚ ƌŝƐŬ ĨĂĐƚŽƌƐ ĨŽƌŵŝƐƵƐĞ ĂŶĚ ƵŶĚĞƌƐƚĂŶĚ ŝŶƐƚƌƵĐƚŝŽŶƐ͘ WƌĞƐĐƌŝƉƚŝŽŶŵƵƐƚ ďĞǁƌŝƚƚĞŶǁŝƚŚ Ă
ƐƚĂƚĞŵĞŶƚƚŚĂƚŝƚŵĂǇŶŽƚďĞƌĞŶĞǁĞĚ͘
ŽŶƚƌĂŝŶĚŝĐĂƚŝŽŶƐĨŽƌE^/Ɛ
Ͳ ,ǇƉĞƌƐĞŶƐŝƚŝǀŝƚǇ;ϭϬйŽĨƉĂƚŝĞŶƚƐǁŝƚŚĂƐƚŚŵĂͿ
Ͳ dƌĞĂƚŵĞŶƚǁŝƚŚĂŶƚŝĐŽĂŐƵůĂŶƚƐ
Ͳ <ŝĚŶĞǇĚĞĨŝĐŝĞŶĐǇ
Ͳ 'ĂƐƚƌŝĐƵůĐĞƌ
Ͳ ĂƌĚŝŽǀĂƐĐƵůĂƌĚŝƐĞĂƐĞ;ĂĐĐŽƌĚŝŶŐƚŽƚŚĞĚĞŐƌĞĞŽĨƐĞǀĞƌŝƚǇͿ
Ͳ ;ZĞůĂƚŝǀĞĐŽŶƚƌĂŝŶĚŝĐĂƚŝŽŶĨŽƌĂŐĞхϳϬǇĞĂƌƐ͖ŚŝŐŚĚŽƐĞƐŽĨE^/ƐĐĂŶďƵƌĚĞŶƚŚĞŬŝĚŶĞǇƐͿ
KďƐĞƌǀĞĐŽŶƚƌĂŝŶĚŝĐĂƚŝŽŶƐͬĐĂƵƚŝŽŶǁŝƚŚŽƉŝŽŝĚƐ͊
Ͳ ,ǇƉĞƌƐĞŶƐŝƚŝǀŝƚǇ
Ͳ ^ůĞĞƉĂƉŶĞĂ;ŽďƐƚƌƵĐƚŝǀĞͬĐĞŶƚƌĂůͿ͗dƌĂŵĂĚŽůDzďĞƵƐĞĚŝŶŵŝůĚƐůĞĞƉĂƉŶĞĂ
Ͳ dĞŶĚĞŶĐǇƚŽďŝůŝĂƌǇƐƉĂƐŵƐ͗EKƉĂƌĂĐĞƚĂŵŽůͬĐŽĚĞŝŶĞ
Ͳ ZĞƐƉŝƌĂƚŽƌǇƉƌŽďůĞŵƐ͗ƌŽŶĐŚŽƉƵůŵŽŶĂƌǇĚŝƐĞĂƐĞ;ĚĞƉĞŶĚŝŶŐŽŶƐĞǀĞƌŝƚǇͿ͕ŶĞƵƌŽŵƵƐĐƵůĂƌĚŝƐŽƌĚĞƌƐ͗EKŽƉŝŽŝĚƐ
Ͳ ,ĞƉĂƚŝĐŝŵƉĂŝƌŵĞŶƚ͗EKǁŝƚŚƉĂƌĂĐĞƚĂŵŽůͬĐŽĚĞŝŶĞ͕ŽƚŚĞƌƐĂĐĐŽƌĚŝŶŐƚŽƚŚĞĚĞŐƌĞĞŽĨƐĞǀĞƌŝƚǇ
Ͳ ZĞŶĂůŝŵƉĂŝƌŵĞŶƚ͗KƉŝŽŝĚƐĂĐĐŽƌĚŝŶŐƚŽĚĞŐƌĞĞŽĨƐĞǀĞƌŝƚǇ
Ͳ zWϮϲƵůƚƌĂĨĂƐƚŵĞƚĂďŽůŝƚĞ;ŬŶŽǁŶŽƌĂƚͲƌŝƐŬďĂƐĞĚŽŶĞƚŚŶŝĐŝƚǇͿ͗EKƉĂƌĂĐĞƚĂŵŽůͬĐŽĚĞŝŶĞŽƌƚƌĂŵĂĚŽů
o ŽĚĞŝŶĞŝƐŵĞƚĂďŽůŝǌĞĚƌĂƉŝĚůǇƚŽŵŽƌƉŚŝŶĞĂŶĚŵĂǇĂĐĐƵŵƵůĂƚĞ͕ǁŚŝĐŚŝƐƌĞĨůĞĐƚĞĚŝŶĚĞĐƌĞĂƐĞĚĂůĞƌƚŶĞƐƐ
ĂŶĚƌĞƐƉŝƌĂƚŽƌǇĚĞƉƌĞƐƐŝŽŶ
o dŚĞƐĂŵĞƌŝƐŬǁŝƚŚƚƌĂŵĂĚŽů;ƉĂƌƚŽĨƚŚĞĞĨĨĞĐƚŝƐƚŚƌŽƵŐŚƚŚĞŽƉŝŽŝĚƌĞĐĞƉƚŽƌͿ
o WƌĞǀĂůĞŶĐĞй ŝŶĚŝĨĨĞƌĞŶƚĞƚŚŶŝĐŐƌŽƵƉƐ͗ĂƐƚĨƌŝĐĂ ;ƚŚŝŽƉŝĂ͕ ^ŽŵĂůŝĂͿϮϵй͕DŝĚĚůĞĂƐƚϮϬй͕ĨƌŝĐĂŶ
ŵĞƌŝĐĂŶϯʹϳй͕ƐŝĂϭʹϮй͕EŽƌƚŚĞƌŶƵƌŽƉĞϭʹϮй͕&ŝŶŶŝƐŚϳй͕DĞĚŝƚĞƌƌĂŶĞĂŶĐŽƵŶƚƌŝĞƐϱʹϭϬй
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APPENDIX 3
WK^dKWZd/sW/ED/d/KE&KZW/dZ/dKE^/>>dKDzWd/Ed
ZĞĐŽŵŵĞŶĚĂƚŝŽŶĨŽƌƉŚǇƐŝĐŝĂŶĂƚƚŚĞ,ĞůƐŝŶŬŝhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂů͕ĞƉĂƌƚŵĞŶƚŽĨKƚŽƌŚŝŶŽůĂƌǇŶŐŽůŽŐǇͶ,ĞĂĚ
ĂŶĚEĞĐŬ^ƵƌŐĞƌǇ
WĂŝŶŵĞĚŝĐĂƚŝŽŶŝƐĚĞƚĞƌŵŝŶĞĚŝŶĚŝǀŝĚƵĂůůǇ͕ƚĂŬŝŶŐŝŶƚŽĂĐĐŽƵŶƚƚŚĞƉƌŽĐĞĚƵƌĞ͕ƚŚĞƉĂƚŝĞŶƚΖƐƵŶĚĞƌůǇŝŶŐĐŽŶĚŝƚŝŽŶƐ͕ĂŐĞĂŶĚ
ǁĞŝŐŚƚ͘ZĞŵĞŵďĞƌƚŚĞƌĞĐŝƉĞ^ŝĐ͊ǁŚĞŶƚŚĞĚŽƐĞĞǆĐĞĞĚƐƚŚĞŝŶƐƚƌƵĐƚŝŽŶƐŝŶWŚĂƌŵĂĐĂ&ĞŶŶŝĐĂ͘
DĞĚŝĐĂƚŝŽŶǁŚĞŶƚŚĞƉĂƚŝĞŶƚĚŽĞƐŶŽƚŚĂǀĞĐŽŶƚƌĂŝŶĚŝĐĂƚŝŽŶƐ;ƉƌŝŶĐŝƉůĞƐĨŽƌƚŚĞŽƉĞƌĂƚŝŽŶŽĨƚŽŶƐŝůƐͿ͗
Ͳ ĚĞŶŽƚŽŵǇ͗ƉĂƌĂĐĞƚĂŵŽůнŝďƵƉƌŽĨĞŶͬŶĂƉƌŽǆĞŶ
Ͳ dŽŶƐŝůůŽƚŽŵǇ͗ƉĂƌĂĐĞƚĂŵŽůнŝďƵƉƌŽĨĞŶͬŶĂƉƌŽǆĞŶ
Ͳ dŽŶƐŝůůĞĐƚŽŵǇ͗
o ƉĂƌĂĐĞƚĂŵŽůнŝďƵƉƌŽĨĞŶͬŶĂƉƌŽǆĞŶнƚƌĂŵĂĚŽůŝĨŶĞĐĞƐƐĂƌǇ;ƚŝƚƌĂƚŝŽŶĂƚŚŽƐƉŝƚĂůͿ
o KZŝďƵƉƌŽĨĞŶͬŶĂƉƌŽǆĞŶнƉĂƌĂĐĞƚĂŵŽůͬĐŽĚĞŝŶĞ;хϭϮǇƌƐŽŶůǇĂŶĚŝŶĚŝĐĂƚŝŽŶŽƚŚĞƌƚŚĂŶƐŶŽƌŝŶŐͬƐůĞĞƉ
ĂƉŶĞĂͿ
WĂƌĂĐĞƚĂŵŽů͗
Ͳ dŚĞĨŝƌƐƚϮĚĂǇƐϭϬϬŵŐͬŬŐͬĚĂǇĚŝǀŝĚĞĚŝŶƚŽϯͲϰĚŽƐĞƐ;Ğ͘Ő͘ϮϱŵŐͬŬŐǆϰͿ͕ĨŽůůŽǁĞĚďǇϲϬŵŐͬŬŐͬĚĂǇĚŝǀŝĚĞĚŝŶƚŽϯ
ĚŽƐĞƐ;ϮϬŵŐͬŬŐǆϯͿƉĞƌŽƌĂůůǇ;ŵĂǆϯŐͬĚĂǇͿ
Ͳ WĂƌĂĐĞƚĂŵŽůŵŝǆƚƵƌĞϮϰŵŐͬŵůŽƌƚĂďůĞƚƐϭϮϱŵŐ͕ϮϱϬŵŐ͕ϱϬϬŵŐƉĞƌŽƌĂůůǇ͘
E^/Ɛ͗
Ͳ EĂƉƌŽǆĞŶŵŝǆƚƵƌĞϮϱŵŐͬŵů;ϱŵŐͬŬŐǆϮͿƉĞƌŽƌĂůůǇ͘
Ͳ /ďƵƉƌŽĨĞŶϰϬŵŐͬŬŐͬĚĂǇĚŝǀŝĚĞĚŝŶϯĚŽƐĞƐƉĞƌŽƌĂůůǇͬƉĞƌƌĞĐƚƵŵ͕ƉĞƌŽƌĂůŵĂǆ͘ĚŽƐĞϮϰϬϬŵŐͬĚĂǇ͘
tĞĂŬKƉŝŽŝĚƐ͗
Ͳ ŽĚĞŝŶĞ͗
o /ŶzWϮϲƵůƚƌĂͲĨĂƐƚŵĞƚĂďŽůŝǌĞƌƐ͕ĐŽĚĞŝŶĞŝƐŵĞƚĂďŽůŝǌĞĚƌĂƉŝĚůǇƚŽŵŽƌƉŚŝŶĞĂŶĚŵĂǇĂĐĐƵŵƵůĂƚĞ͕ǁŚŝĐŚ
ŝƐƌĞĨůĞĐƚĞĚŝŶĚĞĐƌĞĂƐĞĚĂůĞƌƚŶĞƐƐĂŶĚƌĞƐƉŝƌĂƚŽƌǇĚĞƉƌĞƐƐŝŽŶ͘dŚĞƐĂŵĞƌŝƐŬŝƐǁŝƚŚƚƌĂŵĂĚŽů;ƉĂƌƚŽĨƚŚĞ
ĞĨĨĞĐƚŝƐǀŝĂƚŚĞŽƉŝŽŝĚƌĞĐĞƉƚŽƌͿ;ĞƚŚŶŝĐĂƚͲƌŝƐŬŐƌŽƵƉƐ͕ƐĞĞƌĞĐŽŵŵĞŶĚĂƚŝŽŶĨŽƌĂĚƵůƚƐͿ͘
o /ŶƉĂƚŝĞŶƚƐŽǀĞƌϭϮǇĞĂƌƐŽĨĂŐĞǁŚŽŚĂǀĞƵŶĚĞƌŐŽŶĞƚŽŶƐŝůůĞĐƚŽŵǇͬĂĚĞŶŽƚŽŶƐŝůůĞĐƚŽŵǇĨŽƌŝŶĚŝĐĂƚŝŽŶƐ
ŽƚŚĞƌƚŚĂŶƐŶŽƌŝŶŐͬƐůĞĞƉĂƉŶĞĂ͕ĂƚĚŝƐĐƌĞƚŝŽŶ͗ƉĂƌĂĐĞƚĂŵŽůϱϬϬŵŐͬĐŽĚĞŝŶĞϯϬŵŐ;ƐŝŶŐůĞĚŽƐĞŽĨĐŽĚĞŝŶĞ
Ϭ͘ϱͲϭŵŐͬŬŐͿ͘
Ͳ dƌĂŵĂĚŽů͗
o /ĨƉĂŝŶĂĨƚĞƌƚŽŶƐŝůůĞĐƚŽŵǇŝƐƐĞǀĞƌĞŝŶƉĂƚŝĞŶƚƐǇŽƵŶŐĞƌƚŚĂŶϭϮǇĞĂƌƐŽĨĂŐĞ͕ƚƌĂŵĂĚŽůŵĂǇďĞƚŝƚƌĂƚĞĚĂƚ
ŚŽƐƉŝƚĂůƚŽĚĞƚĞƌŵŝŶĞƚŚĞĂƉƉƌŽƉƌŝĂƚĞŵŝŶŝŵĂůĞĨĨĞĐƚŝǀĞĚŽƐĞ;ƵƐƵĂůůǇĂŵĂǆŝŵƵŵŽĨϭŵŐͬŬŐϭʹϯƚŝŵĞƐ
ĚĂŝůǇĂƐŶĞĞĚĞĚͿ͘&ŽůůŽǁͲƵƉŵƵƐƚďĞĂƚůĞĂƐƚϯͲϰŚŽƵƌƐ͘
o WĂƚŝĞŶƚƐŽůĚĞƌƚŚĂŶϭϮǇĞĂƌƐŽĨĂŐĞŽƉĞƌĂƚĞĚĨŽƌƚŽŶƐŝůůĞĐƚŽŵǇͬĂĚĞŶŽƚŽŶƐŝůůĞĐƚŽŵǇĨŽƌŽƚŚĞƌƚŚĂŶƐŶŽƌŝŶŐͬ
ƐůĞĞƉĂƉŶĞĂ͗dƌĂŵĂůϱϬŵŐĐĂƉƐƵůĞƐϭͲϮǆϯͲϰͬĚĂǇ;ƐŝŶŐůĞĚŽƐĞϭͲϮŵŐͬŬŐͿ͘

